Spinal access and neural localization

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to methods and apparatus for modifying tissue in a patient.

Many pathological conditions in the human body may be caused by enlargement, movement, displacement and/or a variety of other changes of bodily tissue, causing the tissue to press against (or “impinge on”) one or more otherwise normal tissues or organs. For example, a cancerous tumor may press against an adjacent organ and adversely affect the functioning and/or the health of that organ. In other cases, bony growths (or “bone spurs”), arthritic changes in bone and/or soft tissue, redundant soft tissue, or other hypertrophic bone or soft tissue conditions may impinge on nearby nerve and/or vascular tissues and compromise functioning of one or more nerves, reduce blood flow through a blood vessel, or both. Other examples of tissues which may grow or move to press against adjacent tissues include ligaments, tendons, cysts, cartilage, scar tissue, blood vessels, adipose tissue, tumor, hematoma, and inflammatory tissue.

One specific example of a condition caused by tissue impingement is spinal stenosis. Spinal stenosis occurs when neural tissue and/or vascular tissue in the spine become impinged by one or more structures pressing against them (“neural and/or neurovascular impingement”), causing one or more symptoms. This impingement of tissue may occur in one or more of several different areas in the spine, such as in the central spinal canal (the vertical passage through which the spinal cord and cauda equina extends), the lateral recesses of the spinal canal, or one or more intervertebral foramina (the openings through which nerve roots branching from the spinal cord pass).

For explanatory purposes, FIG. 1 is offered to show an approximate top view of a vertebra (one of the bones of the spinal column) with the cauda equina (the horsetail-shaped bundle of nerves that extends from the base of the spinal cord through the central spinal canal) shown in cross section and two nerve roots exiting the central spinal canal and extending through intervertebral foramina on either side of the vertebra. (FIG. 1 is not drawn to exact scale and is intended for exemplary purposes only. It should be emphasized here that the drawing figures appended to this application are not intended to be precisely anatomically correct and are provided for exemplary purposes to facilitate description.) The spinal cord and cauda equina run vertically along the spine through the central spinal canal, while nerve roots branch off of the spinal cord and cauda equina between adjacent vertebrae and extend through the intervertebral foramina.

One common cause of spinal stenosis is buckling and thickening of the ligamentum flavum (one of the ligaments attached to and connecting the vertebrae), as shown in FIG. 1. Buckling or thickening of the ligamentum flavum may impinge on one or more neurovascular structures, dorsal root ganglia, nerve roots and/or the spinal cord itself. Another common cause of neural and neurovascular compression within the spine is disease of one or more of the intervertebral discs (the malleable discs between adjacent vertebrae), which may lead to collapse, bulging or herniation of the disc. In FIG. 1, an intervertebral disc is shown with three solid-tipped arrows demonstrating how the disc might bulge or herniate into the central spinal canal to impinge upon the spinal cord, cauda equina and/or individual nerve roots. Other causes of neural and neurovascular impingement in the spine include: hypertrophy of one or more facet joints (also known as zygopophaseal joints, facet joints provide articulation between adjacent vertebrae—two vertebral facet superior articular processes are shown in FIG. 1); formation of osteophytes (bony growths or “bone spurs”) on vertebrae; spondylolisthesis (sliding of one vertebra relative to an adjacent vertebra); and (facet joint) synovial cysts. Disc, bone, ligament or other tissue may impinge on the spinal cord, the cauda equina, branching spinal nerves and/or blood vessels in the spine to cause loss of function, ischemia (shortage of blood supply) and even permanent damage of neural or neurovascular tissue. In a patient, this may manifest as pain, impaired sensation and/or loss of strength or mobility.

In the United States, spinal stenosis occurs with an incidence of between 4% and 6% of adults aged 50 and older and is the most frequent reason cited for back surgery in patients aged 60 and older. Conservative approaches to the treatment of symptoms of spinal stensosis include systemic medications and physical therapy. Epidural steroid injections may also be utilized, but they do not provide long lasting benefits. When these approaches are inadequate, current treatment for spinal stenosis is generally limited to invasive surgical procedures to remove vertebral ligament, cartilage, bone spurs, synovial cysts, cartilage, and bone to provide increased room for neural and neurovascular tissue. The standard surgical procedure for spinal stenosis treatment includes laminectomy (complete removal of the lamina (see FIG. 1) of one or more vertebrae) or laminotomy (partial removal of the lamina), followed by removal (or “resection”) of the ligamentum flavum. In addition, the surgery often includes partial or occasionally complete facetectomy (removal of all or part of one or more facet joints between vertebrae). In cases where a bulging intervertebral disc contributes to neural impingement, disc material may be removed surgically in a discectomy procedure.

Removal of vertebral bone, as occurs in laminectomy and facetectomy, often leaves the effected area of the spine very unstable, leading to a need for an additional highly invasive fusion procedure that puts extra demands on the patient's vertebrae and limits the patient's ability to move. In a spinal fusion procedure, the vertebrae are attached together with some kind of support mechanism to prevent them from moving relative to one another and to allow adjacent vertebral bones to fuse together. Unfortunately, a surgical spine fusion results in a loss of ability to move the fused section of the back, diminishing the patient's range of motion and causing stress on the discs and facet joints of adjacent vertebral segments. Such stress on adjacent vertebrae often leads to further dysfunction of the spine, back pain, lower leg weakness or pain, and/or other symptoms. Thus, while laminectomy, facetectomy, discectomy, and spinal fusion frequently improve symptoms of neural and neurovascular impingement in the short term, these procedures are highly invasive, diminish spinal function, drastically disrupt normal anatomy, and increase long-term morbidity above levels seen in untreated patients.

Therefore, it would be desirable to have less invasive methods and devices for addressing neural and neurovascular impingement in a spine. Ideally, methods and devices for addressing impingement in spine would treat one or more target tissues while preventing unwanted effects on adjacent or nearby non-target tissues. Also ideally, such methods and devices would be minimally invasive and reduce impingement without removing significant amounts of vertebral bone, joint, or other spinal support structures, thereby avoiding the need for spinal fusion and, ideally, reducing the long-term morbidity levels resulting from currently available surgical treatments. It may also be advantageous to have less invasive methods and devices for modifying target tissues in parts of the body other than the spine while preventing modification of non-target tissues.

One challenge in developing less invasive or less damaging devices and techniques for treating neural and neurovascular impingement is reducing the risk of any unwanted damage to nerve or vascular tissue. This challenge may prove daunting, because the tissue impinging on neural or neurovascular tissue in the spine is typically located in small, confined areas, such as intervertebral foramina, the central spinal canal and the lateral recesses of the central spinal canal, which typically have very little open space and are difficult to see without removing spinal bone. Thus, it would be highly desirable to have methods and devices to facilitate placement of a tissue modification device in a desired location in the spine for performing a tissue modification procedure while preventing unwanted damage to surrounding tissues. Ideally, such methods and devices would allow a physician performing a tissue modification procedure to know where neural tissue and non-neural tissue was located relative to a tissue modification device, to help assure safety of the procedure. At least some of these objectives will be met by the present invention.

2. Description of Background Art

Flexible wire saws and chain saws, such as threadwire saws (T-saws) and Gigli saws, have been used since the late 1800s to saw through or file/abrade bone and other tissue in the human body. See, for example, Brunori A et al., “Celebrating the Centenial (1894-1994): Leonardo Gigli and His Wire Saw,” J Neurosurg 82:1086-1090, 1995. An example of one such saw is described in U.S. Pat. No. 8,250, issued to P. A. Stohlmann on Nov. 28, 1876. A description of using a T-saw to cut vertebral bone is provided in Kawahara N et al., “Recapping T-Saw Laminoplasty for Spinal Cord Tumors,” SPINE Volume 24, Number 13, pp. 1363-1370.

A method and apparatus for treating spinal stenosis is described in PCT Patent Application Pub. No. WO 01/08571. A surgical instrument for removing cartilage from a knee cavity is described in U.S. Pat. No. 3,835,859. Various devices for stimulating or locating nerve tissue are described in U.S. Pat. Nos. 4,962,766, 5,284,154, 6,146,380, 6,466,817, 6,500,128, 6,564,078 and 6,760,616 and U.S. Patent Application Pub. Nos. 2004/0199084 and 2005/0182454.

SUMMARY OF THE INVENTION

In various embodiments, the present invention provides methods, apparatus and systems for modifying tissue in a patient. Generally, the methods, apparatus and systems may involve using an elongate, at least partially flexible tissue modification device having one or more tissue modification members to modify one or more target tissues. The tissue modification device may be configured such that when the tissue modification member (or members) is in a position for modifying target tissue, one or more sides, surfaces or portions of the tissue modification device configured to avoid or prevent damage to non-target tissue will face non-target tissue. In various embodiments, during a tissue modification procedure, anchoring or tensioning forces may be applied at or near either or both of a distal portion and a proximal portion of the tissue modification device, either inside or outside the patient, to urge the tissue modifying member(s) against target tissue. When anchoring force is applied to one end of a device, for example, pulling or tensioning force may be applied to the unanchored end of the device. In some embodiments, tensioning force may be applied at or near both ends of a device.

When the tissue modifying members of a tissue modification device are in contact with target tissue, they may then be activated to modify target tissue while avoiding damage to surrounding, non-target tissues. In various embodiments, various alternative means may be employed for avoiding such unwanted damage. For example, in some embodiments, the tissue modifying members may be generally disposed along a length of the tissue modification device that approximates a length of target tissue to be modified. In some embodiments, tissue is modified without moving the tissue modification members significantly beyond the target tissue. Applying tensioning or anchoring forces at or near the proximal and distal portions of an at least partially flexible tissue modification device may enhance the ability of the device's tissue modification members to work effectively within a limited treatment space and may also allow the device to have a relatively small profile, thus facilitating its use in less invasive procedures and in other procedures in which alternative approaches to target tissue may be advantageous.

As used above and throughout the present application, the phrase “applying an anchoring force” means applying a force to maintain a portion of a device, or a device as a whole, substantially stable or motion-free. Applying an anchoring force, therefore, is not limited to preventing all movement of a device, and in fact, a device to which an anchoring force is applied may actually move in one or more directions in some embodiments. In other embodiments, an anchoring force is applied to maintain a portion of a device substantially stable, while another portion of the device is allowed to move more freely. As will be described in further detail below, applying an anchoring force in one embodiment involves a user of a device grasping the device at or near one of its ends, typically though not necessarily by use of a handle. In other embodiments, devices may use one or more anchoring members to apply an anchoring force. In a number of embodiments, an anchoring force may be applied with or against one or more tissues of a patient's body, and the tissue(s) may often move even as they apply (or help apply) the force. Thus, again, applying an anchoring force to a device does not necessarily mean that all motion of the device is eliminated. Of course, in some embodiments, it may be possible and desirable to eliminate all movement or substantially all movement of a device (or portion of a device), and in some embodiments anchoring force may be used to do so.

In some embodiments, the described methods, apparatus and systems may be used to modify tissue in a spine, such as for treating neural impingement, neurovascular impingement and/or spinal stenosis. In alternative embodiments, target tissues in other parts of the body may be modified.

In one aspect of the present invention, a method for locating neural tissue in a patient body may involve: advancing a probe along a natural tissue interface between the neural tissue and another tissue in the body, the probe having a first surface oriented toward the neural tissue and a second surface oriented away from the neural tissue; delivering a first electrical current to a first electrode along the first surface of the probe; delivering a second electrical current to a second electrode along the second surface of the probe; and verifying that the first surface of the advanced probe remains oriented toward the neural tissue and the second surface remains oriented away from the neural tissue by monitoring neural response to the first and second electrical currents. In some embodiments, the probe may include an elongate flattened body having an axis and a distal end, the first and second surfaces comprising opposed major surfaces of the elongate body, the electrodes extending along an electrode length proximally of the distal end sufficiently to verify that injury to the neural tissue will be inhibited when treatment of the other tissue is directed along the electrode length from a path of the probe. Optionally, the tissue interface may include two adjacent tissue planes, and advancing the probe may cause the distal end of the probe to dissect the neural tissue from the other tissue along the tissue interface, the other tissue comprising an impinging tissue and being harder than the neural tissue. The method may optionally also involve treating the other tissue by directing treatment from the probe path along the electrode length in the verified orientation of the second electrode so as to reduce impingement of the neural tissue by the other tissue.

In some embodiments, advancing the probe involves advancing a distal portion of the probe along an interface between a bone or ligament surface and a soft tissue surface so that at least a part of the distal portion of the advanced probe extends into an intervertebral foramen of a spine. Optionally, the method may further include advancing a curved, shape-memory guide member having at least one lumen out of a distal opening on the probe device.

In some embodiments, the method may involve: determining a first threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the first electrode; determining a second threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the second electrode; and comparing the first and second threshold amounts of current, to determine which of the first and second surfaces is closest to the neural tissue. For example, in some embodiments, the threshold amount of current applied to the electrode closest to the neural tissue may be less than about 1 milliamp, and the amount of threshold current applied to the electrode farthest from the neural tissue may be greater than about 2 milliamps. In some embodiments, comparing the first and second threshold amounts of current may involve calculating a ratio of the threshold amount of current applied to the electrode farthest from the neural tissue compared to the threshold amount of current applied to the electrode closest to the neural tissue. For example, in some cases such a ratio may be greater than or equal to 2.

In some embodiments, monitoring the neural response to the first and second currents comprises monitoring somatosensory evoked potentials (SSEP), motor evoked potentials (MEP), electromyography (EMG), visible muscle twitch and/or tactile muscle twitch.

In another aspect of the present invention, a method for positioning a guidewire between neural tissue and adjacent tissue in a patient body involves: positioning a distal portion of a probe device between neural tissue and tissue adjacent the neural tissue in the body; delivering electrical current to a first electrode coupled with a first surface of the distal portion of the probe; determining a first threshold amount of electrical current required to provoke a response in the neural tissue via the first electrode; determining a location of the neural tissue relative to the first surface of the distal portion, based on the first threshold amount of current; and advancing a guidewire through an opening in the distal portion of the probe. Some embodiments may further involve, before advancing the guidewire through the opening, delivering electrical current to a second electrode coupled with a second surface of the distal portion; determining a second threshold amount of electrical current required to provoke a response in the neural tissue via the second electrode; and comparing the first and second threshold amounts of current, to determine which of the first and second surfaces is closest to the neural tissue.

In some embodiments, positioning the distal portion may involve positioning at least part of the distal portion in an intervertebral foramen of a spine. In some embodiments, positioning the distal portion may involve advancing a shaped portion of the probe along a complementary shaped portion of a decompression implant located between two vertebrae of the spine. In some embodiments, positioning the distal portion may involve advancing a shaped portion of the probe through a complementary shaped portion of a tubular spinal access conduit. In some embodiments, positioning the distal portion may involve advancing a curved, shape-memory guide member having at least one lumen out of a distal opening on the probe device. For example, advancing the guide member may involve pushing a slide member coupled with the guide member and disposed on a shaft of the probe. Advancing the guidewire may also involve advancing through the lumen of the guide member. In some embodiments, advancing the guidewire at least partially straightens the curved guide member.

In some embodiments, positioning the distal portion involves articulating at least part of the distal portion. Advancing the guidewire may involve advancing a sharp-tipped guidewire through the distal opening and then through tissue in the body. The method may optionally further include removing the probe device from the body while leaving the guidewire in place between the neural tissue and adjacent tissue. Such embodiments may optionally further include advancing at least one tissue modification device over the guidewire to position a portion of the device between the neural tissue and adjacent tissue and performing a tissue modifying procedure with the tissue modification device. An alternative embodiment may involve coupling a distal portion of a tissue modification device at or near one end of the guidewire, pulling the guidewire to pull a portion of the tissue modification device to a desired position between the neural tissue and adjacent tissue, and performing a tissue modifying procedure with the tissue modification device. Either of these last method embodiments may also optionally include delivering electrical current to at least one electrode coupled with the tissue modification device to confirm a location of the neural tissue relative to the device.

In another aspect of the present invention, a device for advancing a guidewire in a human body may include: an elongate probe having a proximal portion, a distal portion and at least one lumen having a proximal opening and a distal opening; a curved guide member slidably disposed within the lumen of the probe, wherein at least a portion of the guide member is configured to be advanced out of the distal opening of the lumen to assume a curved shape, and wherein the guide member includes at least one guidewire lumen; and a slide member coupled with the probe and the guide member to advance the guide member out of the distal opening of the probe. In some embodiments, the device may further include at least one signal transmitter coupled with at least one of the probe and the guide member and connectible with at least one energy source. For example, in one embodiment, the at least one signal transmitter may include a first electrode coupled with a first surface of the probe at or near the distal portion and connectible with the at least one energy source and at least a second electrode coupled with a second surface of the probe at or near the distal portion and connectible with the energy source. Various alternative embodiments may additionally include a third electrode, fourth electrode or more on various surfaces. In another alternative embodiment, the at least one signal transmitter may include at least one tissue distinguishing member selected from the group consisting of ultrasound transducers, piezoelectric transducers, visualization devices and optical coherence tomography devices.

In some embodiments, the elongate probe may include a curve or bend at or near the distal portion. For example, such a curve or bend and the distal portion may be configured to facilitate passage of at least part of the distal portion into an intervertebral foramen of a spine. In alternative embodiments, the probe may be predominantly rigid, at least part of the probe may flexible, and/or at least part of the distal portion of the probe may be articulated to form more than one curved shape. In one articulating embodiment, the device may include at least one wire coupled with the distal portion for pushing or pulling to articulate the distal portion.

In one embodiment, the probe may include at least two lumens, wherein one lumen is configured to accept the guide member and the other lumen(s) comprise at least one of a visualization lumen, a suction lumen and a fluid introduction lumen. Such an embodiment may optionally further include a visualization device disposed in the visualization lumen, such as but not limited to an endoscope, fiber optic, charge-coupled device (CCD) or complementary metal-oxide semiconductor (CMOS) device.

In some embodiments, the proximal opening of the probe lumen may be sized to allow passage of a guidewire, so that the guidewire may be passed into the proximal opening, into the guidewire lumen of guide member, and out a distal opening of the guide member. Also in some embodiments, at least a portion of the probe may be shaped to slide along a complementary shaped portion of a spinal decompression implant located between two vertebrae or to slide through a complementary shaped portion of a tubular spinal access conduit.

In various embodiments, the guide member may have a cross-sectional shape such as but not limited to round, oval, rectangular, triangular, elliptical and figure-8. In some embodiments, the guide member may include a shape memory material. In some embodiments, the guide member may be sufficiently flexible that when a guidewire is passed through its lumen, the guide member at least partially straightens.

In another aspect of the present invention, a system for localizing neural tissue in a patient body, the neural tissue being separated from an impinging tissue by a natural tissue interface, may include: a probe having a proximal end and a distal end with an axis therebetween, the distal end suitable for advancing distally along the natural tissue interface, the probe having first and second laterally oriented surfaces; a first signal transmitter disposed along the first surface of the probe; a second signal transmitter disposed along the second surface of the probe, the first and second signal transmitters defining an axial verification length; and a signal source for generating a neural localization signal, the source selectively coupleable with the first and second signal transmitters of the probe such that, by monitoring a response to the neural localization signal when the probe has been advanced along the natural interface with the first surface oriented toward the neural tissue and the second surface oriented away from the neural tissue, orientation of the neural tissue relative to the probe axis throughout the axial verification length can be safely verified.

In one embodiment, the first and second signal transmitters may comprise first and second electrodes, the signal source comprising an electrical source for generating electrical neural stimulation signals. Optionally, such a system may further include: a neural response sensor; and a processor coupled to the electrical source and the sensor, the processor configured to verify, in response to the neural response to the stimulation applied by the first electrode and the second electrode, that the first surface is oriented toward the neural tissue and the second electrode is oriented away from the neural tissue. In an alternative embodiment, the first and second signal transmitters may comprise first and second ultrasound transducers, the signal source comprising an ultrasound generator.

In some embodiments, the distal portion of the shaft is configured to facilitate its passage into an intervertebral foramen of a spine. Optionally, in such embodiments, at least a portion of the shaft of the probe may be shaped to slide along a complementary shaped portion of a spinal decompression implant located between two vertebrae. Such a system may further include at least one spinal decompression implant for placing between two vertebrae. In another embodiment, at least a portion of the shaft of the probe may be shaped to slide through a complementary shaped portion of a tubular spinal access conduit. Such a system may optionally further include at least one tubular spinal access conduit for gaining access to the spine through the body.

Various additional features may be included in alternative embodiments of the system. For example, in one embodiment, the system may further include at least one of an ultrasound transducer, a piezoelectric crystal, a visualization device, and an optical coherence tomography device coupled with the probe. In some embodiments, the probe may further comprise at least one lumen disposed longitudinally through at least a portion of its length, the system further comprising a curved, hollow guide member slidably disposed within, and configured to be advanced out of a distal opening of, the probe lumen, wherein the guide member comprises at least one guidewire lumen. Such an embodiment may optionally further include a slide member coupled with the probe and the guide member to advance the guide member out the distal opening of the probe. In one embodiment, the system may further include a guidewire and at least one tissue removal device for advancing along or being pulled into position by the guidewire to remove tissue from the body. As another optional feature, in one embodiment the system may further include at least one sizing probe configured to perform at least one of the functions of assessing an amount of space between tissues before advancing the probe, increasing the amount of space between tissue before advancing the probe, and assessing the amount of space between tissues after performing a tissue modification procedure.

These and other aspects and embodiments are described more fully below in the Detailed Description, with reference to the attached Drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is cross-sectional view of a spine, showing a top view of a lumbar vertebra, a cross-sectional view of the cauda equina, and two exiting nerve roots;

FIG. 2 is a cross-sectional view of a portion of a patient's back and spine, showing part of a vertebra and apparatus in place for modifying tissue according to one embodiment of the present invention;

FIG. 3A is a perspective view of a tissue modification device according to one embodiment of the present invention;

FIG. 3B is a perspective view of a portion of the tissue modification device of FIG. 3A;

FIG. 3C is a top view of the portion shown in FIG. 3B;

FIG. 3D is a side view of the portion shown in FIGS. 3B and 3C;

FIGS. 3E and 3F are cross-sectional views of a portion of the tissue modification device taken through lines A-A and B-B, respectively, shown in FIG. 3C;

FIG. 3G is a perspective view of a portion of the tissue modification device of FIGS. 3B-3F, shown with a blade of the device in a closed position according to one embodiment of the present invention;

FIG. 3H is a top view of the portion shown in FIG. 3G;

FIG. 3I is a side view of the portion shown in FIGS. 3G and 3H;

FIG. 4A is a perspective view of a tissue modification device according to one embodiment of the present invention;

FIG. 4B is a perspective view of a portion of the tissue modification device of FIG. 4A;

FIG. 4C is a close-up, perspective view of a portion of the tissue modification device of FIGS. 4A and 4B, showing a tissue modifying member according to one embodiment of the present invention;

FIGS. 5A-5D are cross-sectional views of a spine and demonstrate a method for using a tissue modification device according to one embodiment of the present invention;

FIG. 6A is a cross-sectional view of a portion of a patient's spine and back, with apparatus for modifying tissue in position for modifying spinal tissue and with a distal portion of the apparatus anchored outside the patient according to one embodiment of the present invention;

FIG. 6B is a cross-sectional view of a portion of a patient's spine and back, with apparatus for modifying tissue in position for modifying spinal tissue and with a distal portion of the apparatus anchored inside the patient according to one embodiment of the present invention;

FIGS. 7A-7S are cross-sectional views of a portion of a patient's spine and back, demonstrating a method for introducing apparatus for modifying spinal tissue to an area in the spine for performing the tissue modification according to one embodiment of the present invention;

FIGS. 8A-8F are cross-sectional views of a portion of a patient's spine and back, demonstrating a method for introducing apparatus for modifying spinal tissue to an area in the spine for performing the tissue modification according to an alternative embodiment of the present invention;

FIGS. 9A-9B are cross-sectional views of a portion of a patient's spine and back, demonstrating a method for introducing apparatus for modifying spinal tissue to an area in the spine for performing the tissue modification according to an alternative embodiment of the present invention;

FIGS. 10A and 10B are side views of two access probe devices according to alternative embodiments of the present invention;

FIGS. 10C-10F illustrate a method of placing a guidewire between tissues using the access probe device shown in FIG. 10A according to one embodiment of the present invention;

FIGS. 11A-11E are cross-sectional views of a portion of a patient's spine and back, demonstrating a method for introducing a guidewire and a tissue modification device between target and non-target tissue in the spine according to one embodiment of the present invention;

FIG. 12 is a diagram of a system for providing neural localization according to one embodiment of the present invention;

FIGS. 13A and 13B are diagrammatic side views demonstrating a method for applying energy to electrodes on two surfaces of a probe according to one embodiment of the present invention;

FIGS. 14A and 14B are diagrammatic side views demonstrating a method for applying energy to electrodes on two surfaces of a probe according to the embodiment shown in FIGS. 13A and 13B but with a different location relative to body tissue;

FIGS. 15A and 15C are diagrammatic side views demonstrating a method for applying energy to electrodes on two surfaces of a probe according to an alternative embodiment of the present invention;

FIGS. 15B and 15D are diagrammatic representations of transmitted and reflected signals from and ultrasound transducers of the probes of FIGS. 15A and 15C;

FIGS. 16A-16C are perspective, frontal and side/cross-sectional views, respectively, of a probe device for facilitating guidewire placement in a spine according to one embodiment of the present invention;

FIGS. 17A-17E are perspective views of distal portions of various embodiments of a probe device, demonstrating different numbers and configurations of electrodes according to various embodiments of the present invention;

FIGS. 18A and 18B are perspective views of a probe and a needle, respectively, each with a guide member extension with electrodes according to one embodiment of the present invention;

FIGS. 19A-19C are side views of a distal portion of an articulating probe device according to one embodiment of the present invention;

FIGS. 20A and 20B are frontal and side/cross-sectional views, respectively, of a probe device for facilitation guidewire placement in a spine according to an alternative embodiment of the present invention;

FIG. 20C is a side view of a portion of a guide member of the probe device of FIGS. 20A and 20B;

FIGS. 21A and 21B are side views of a guide member of a probe device according to an alternative embodiment of the present invention;

FIGS. 22A and 22B are side views of probes having different shapes according to alternative embodiments of the present invention;

FIG. 22C is a side view of a probe having yet another shape and having two electrodes according to one embodiment of the present invention;

FIG. 23A is a perspective view of a spinal decompression device and a probe device having a complementary surface shape to slide along the decompression device according to one embodiment of the present invention;

FIG. 23B is a side view of a portion of a spine, showing the spinal decompression device and probe of FIG. 23A in place according to one embodiment of the present invention;

FIG. 24 is a side and perspective view, respectively, of an access port device for accessing a spine and a probe device having a surface shaped to slide through guide member of the access device according to one embodiment of the present invention;

FIG. 25 is a side view of an access port device for accessing a spine, including a probe guide member according to one embodiment of the present invention;

FIG. 26A is a perspective view of a distal portion of an introducer sheath according to one embodiment of the present invention;

FIGS. 26B and 26C are perspective and cross-sectional views, respectively, of a tissue shield device according to one embodiment of the present invention; and

FIGS. 26D and 26E are perspective and cross-sectional views, respectively, of a tissue shield device according to an alternative embodiment of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

Methods, apparatus and systems for modifying tissue in a patient are provided. Methods, apparatus and systems for spinal access and neural localization are also provided. Although the following description and accompanying drawing figures generally focus on tissue modification in spine, in various alternative embodiments any of a number of tissues in any of a number of anatomical locations in a patient may be modified.

Referring to FIG. 2, one embodiment of a tissue modification device 102 may include an elongate body 108 having a proximal portion 107 and a distal portion 109, a proximal handle 104 with an actuator 106 coupled with proximal portion 107, one or more tissue modifying surfaces or members 110, one or more tissue protective surfaces 112, a guidewire 116 coupled with the distal portion 109, and a distal handle 113 removably couplable with guidewire 116. (FIG. 2, as well as many of the subsequent Figures in this application, is not drawn to scale.) In various embodiments, some of which are described further below, modification device 102 may be introduced into an area for performing a treatment, such as a spine, using any of a number of different introduction methods, devices and systems. In FIG. 2, for example, modification device 102 extends through an introducer device 114 placed through a first incision 240 on the patient's back and into the central spinal canal. Modification device 102 may be advanced through introducer 114, in one embodiment, by coupling distal portion 109 with guidewire 116 and pulling distal portion 109 through introducer 114 by pulling guidewire 116. Distal portion 109 may be further pulled into or through an intervertebral foramen between two adjacent vertebrae (only part of one vertebra is shown in FIG. 2), and out a second (or “distal”) incision or non-incision exit point 242 on the back. When guidewire 116 is advanced through distal exit point 242, it may be coupled with distal handle 113 to facilitate application of anchoring or tensioning force to guidewire 116. In some embodiments, as shown, guidewire 116 may include a beveled distal tip 117 for facilitating advancement of guidewire 116 through tissue. In an alternative embodiment, a modification device may be advanced along a guidewire extending through an introducer, rather than pulling the modification device through the introducer. In another alternative embodiment, a tissue modification device may be advanced into the spine through an open surgical approach. These and other methods for introducing a tissue modification device are described in further detail below.

Generally, tissue modification device 102 may be advanced to a position in the spine such that tissue modifying surface or member 110 faces target tissue to be modified, such as buckled, thickened or otherwise impinging ligamentum flavum tissue as shown in FIG. 2. Modification device 102 is configured such that when tissue modifying member 110 faces target tissue, protective surface(s) 112 face non-target tissue. Protective surface 112 may be simply a length of elongate body 108 or may have one or more protective features, such as a widened diameter, protective or lubricious coating, extendable or expandable barrier, drug-eluting coating or ports, or the like. In some instances, protective surface(s) 112 may act as “non-tissue-modifying” surfaces, in that they may not substantially modify the non-target tissue. In alternative embodiments, protective surface(s) 112 may affect non-target tissue by protecting it in some active way, such as by administering one or more protective drugs, applying one or more forms of energy, providing a physical barrier, or the like.

In some embodiments, once tissue modification device 102 is positioned such that tissue modifying surface or member 110 faces target tissue and protective surface 112 faces non-target tissue, an anchoring or tensioning force may be applied to distal portion 109 of elongate body 108 by applying anchoring or tensioning force to guidewire 116 via distal handle 113. Anchoring or tensioning force may also be applied at or near proximal portion 107 of elongate body 108, such as by pulling on proximal handle 104 (one-directional arrows), and actuator 106 may be used (two-headed arrow) to activate tissue modifying member(s) 110 to modify target tissue. In the example shown, anchoring force is applied to distal handle 113 by a user's hand 244, and proximal handle 104 is pulled proximally (arrows) to apply tensioning force. In an alternative embodiment, hand 244 may directly grasp guide member 116 at or near its distal portion 117 and thus apply anchoring force to it, thus also applying anchoring force to elongate body 108. Tissue modification via tissue modifying members 110 may include cutting, ablating, dissecting, repairing, reducing blood flow in, shrinking, shaving, burring, biting, remodeling, biopsying, debriding, lysing, debulking, sanding, filing, planing, heating, cooling, vaporizing, delivering a drug to, and/or retracting the target tissue. Once tissue has been modified, tissue modification device 102 and any introducer devices 114, guide members 116 or other devices may be removed from the patient.

In various embodiments of the apparatus, tissue modifying member(s) 110 may be disposed along any suitable length of body 108. In one embodiment, for example, such as an embodiment of the device to be used in a spinal treatment, tissue modifying members 110 may be disposed along a length of the device measuring no longer than 10 cm, and preferably no more than 6 cm, and even more preferably no more than 3 cm. In various embodiments, tissue modifying member(s) 110 may include a rongeur, a curette, a scalpel, one or more cutting blades, a scissors, a forceps, a probe, a rasp, a file, an abrasive element, one or more small planes, an electrosurgical device, a bipolar electrode, a unipolar electrode, a thermal electrode, a rotary powered mechanical shaver, a reciprocating powered mechanical shaver, a powered mechanical burr, a laser, an ultrasound crystal, a cryogenic probe, a pressurized water jet, a drug dispensing element, a needle, a needle electrode, or some combination thereof. In various embodiments, all tissue modifying members 110 may be mobile relative to the elongate body, all may be static, or some may be mobile and some may be static. These and other aspects and embodiments are described further below.

Turning now to FIG. 3A-31, more detailed figures of one embodiment of tissue modification device 102 are shown. Referring to FIG. 3A, tissue modification device 102 may include elongate body 108 having proximal portion 107 and distal portion 109, a window 111 disposed along elongate body 108, two tissue modifying blades 110 exposed through window 111, and proximal handle 104 with actuator 106 coupled with proximal portion 107. In the embodiment shown, the tissue modifying members comprise blades 110, although in alternative embodiments other tissue modifying members may be added or substituted.

In various embodiments, elongate body 108 may have any number of dimensions, shapes, profiles and amounts of flexibility. For example, distal portion 109 is shown having a curved shape to demonstrate that at least a portion of elongate body 108 may be flexible. In some embodiments, as discussed in relation to FIG. 2 above, distal portion 109 may comprise a guidewire, while in other embodiments, distal portion may comprise an extension of elongate body 108. In various embodiments, elongate body 108 may have one or more of a round, ovoid, ellipsoid, flat, cambered flat, rectangular, square, triangular, symmetric or asymmetric cross-sectional shape. As shown in FIGS. 3C and 3D, in the pictured embodiment, elongate body 108 has a relatively flat configuration, which may facilitate placement of body 108 between target and non-target tissues. Distal portion 109 of body 108 may be tapered, to facilitate its passage into or through narrow spaces as well as through small incisions on a patient's skin. Body 108 may also include a slightly widened portion around the area of window 111 and blades. In one embodiment, such as an embodiment used for modifying tissue in a spine, body 108 may have a small profile, such as having a height of not more than 10 mm at any point along its length and a width of not more than 20 mm at any point along its length, or more preferably a height not more than 5 mm at any point along its length and a width of not more than 10 mm at any point along its length, or even more preferably a height not more than 2 mm at any point along its length and a width of not more than 4 mm at any point along its length. Body 108 may be long enough to extend through a first incision on a patient, between target and non-target tissue, and out a second incision on a patient. Alternatively, body 108 may be long enough to extend through a first incision, between the target and non-target tissue, and to an anchoring location within the patient. In another alternative embodiment, body 108 may be long enough to extend through a first incision, between the target and non-target tissue, to a location nearby but distal to the target tissue within the patient, with some portion of tissue modification device 102 anchored to a guidewire. In some embodiments, elongate body 108 includes at least one feature for allowing passage of the body over a guidewire or other guide member or to allow passage of one or more guide members over or through body 108. For example, in various embodiments body 108 may include one or more guidewire lumens, rails, tracks, lengthwise impressions or some combination thereof.

In one embodiment, elongate body 108 is predominantly flexible along its length and comprises any suitable flexible material, such as thin, flexible metals, plastics, fabrics or the like. In some embodiments, it may be advantageous to include one or more rigid sections in elongate body 108, such as to impart pushability to a portion of body 108 or to facilitate application of force to tissue modification members 110 without causing unwanted bending or kinking of elongate body 108. In such embodiments, rigidity may be conferred by using additional materials in body 108 or by making the rigid portions thicker or wider or of a different shape.

Proximal handle 104 may have any suitable configuration according to various embodiments. Similarly, actuator 106 may include any of a number of actuation devices in various embodiments. In the embodiment shown in FIG. 3A, actuator 106 comprises a trigger or moving handle portion, which is grasped by a user and pulled or squeezed toward proximal handle 104 to bring blades 110 together to cut tissue. In an alternative embodiment, actuator 106 instead may include a switch or button for activating a radiofrequency surgical ablation tissue modifying member. In yet another embodiment, actuator 106 may include a combination trigger and switch, one or more pull wires, any suitable form of lever and/or some combination thereof.

FIGS. 3B-3D show in greater detail a portion of tissue modification device 102. In these figures, window 111 and blades 110 are more clearly seen. In one embodiment, at least a portion of elongate body 108 and blades 110 may have a slightly curved configuration. In alternative embodiments, at least a portion of elongate body 108 and blades 110 may be flat. In other alternative embodiments, tissue modification members such as blades 110 may be proud to elongate body 108.

Blades 110 include a distal 110a and a proximal blade 110b that reside at the distal and proximal edges, respectively, of window 111 of elongate body 108. Window 111 of body 108 may accommodate both soft and hard tissue when the device is forcibly applied to the surface of a target tissue site. The top view of the distal portion of elongate body 108, shown in FIG. 3C, depicts the angled edges of distal blade 110a and proximal blade 110b, which facilitate shearing of target tissue. In alternative embodiments, blades 110 may have any of a number of alternative shapes and configurations. The distal portion of body 108 may have a very low profile (height compared to width), as shown in side view FIG. 3D, where only blades 110 protrude from the top surface of the elongate body 108. In one embodiment, also as shown in FIG. 3D, a guidewire tube 120 (or lumen) may extend from (or be coupled with) a lower surface of elongate body 108. The lower surface of elongate body 108 is an example of a protective or non-tissue-modifying surface.

In one embodiment, distal blade 110a is coupled with two pull-wires 118, as seen in FIGS. 3C, 3E and 3F. Pull-wires 118 coupled to and translated by actuator 106 on handle 104 may be used to drive distal blade 110a proximally to contact the cutting edge of proximal blade 110b, thus cutting tissue. Other alternative mechanisms for driving blades 110, such as gears, ribbons or belts, magnets, electrically powered, shape memory alloy, electro magnetic solenoids and/or the like, coupled to suitable actuators, may be used in alternative embodiments. As mentioned, in one embodiment distal blade 110a and/or proximal blade 110b may have an outwardly curvilinear shape along its cutting edge. Alternatively, distal blade 110a may have a different blade shape, including flat, rectilinear, v-shaped, and inwardly curvilinear (concave vs. convex). The cutting edge of either blade 110 may have a sharp edge formed by a simple bevel or chamfer. Alternatively or in addition, a cutting edge may have tooth-like elements that interlock with a cutting edge of an opposing blade, or may have corrugated ridges, serrations, rasp-like features, or the like. In various embodiments, both blades 110 may be of equal sharpness, or alternatively one blade 110 may be sharp and the other substantially flat to provide a surface against which the sharp blade 110 may cut. Alternately or in addition, both cutting edges may be equally hard, or a first cutting edge may be harder than a second, the latter of which deflects under force from the first harder edge to facilitate shearing of the target tissue.

FIGS. 3E and 3F show cross-sectional views through elongate body at lines A-A and B-B, respectively, of FIG. 3C. In some embodiments, all or a portion of elongate body 108, such as the lower surface shown in FIG. 3E, may include a lubricious surface for facilitating manipulation of the tool in the surgical space and at the anatomical site. The lubricious lower surface also provides a barrier between blades 110 and non-target tissue in the surgical space. The lower surface may include a guide member lumen 120 to accommodate a guidewire or other access device or rail. FIG. 3E shows distal blade 110 coupled with pull wires 118. FIG. 3F shows proximal blade 110b, which is not coupled with pull wires 118 but rather fixed to body 108. In various alternative embodiments, proximal blade 110b may be movable distally while distal blade 110a is static, both blades may be moved toward one another, or a different number of blades may be used, such as one blade drawn toward a backstop or more than two blades, one or more of which may be mobile. In various alternative embodiments, guide member lumen 120 may be accommodated on a side surface or more centrally within elongate body 108. In further alternative embodiments, the one or more guide member lumens 120 may comprise one or more various cross sectional shapes, for example substantially round, substantially oval, or substantially rectabular, to accommodate alternative guide members, for example flat or rectangular guidewires, needles or rails. In still other alternative embodiments guide member lumen 120 may be adjustably coupled with the elongate body 108 to enable manipulation of the location of the elongate body 108 and therefore the tissue modifying members 110 relative to the guiding member.

Referring now to FIGS. 3G-3I, blades 110 are shown in their closed position. In one embodiment, when distal blade 110a is drawn proximally to cut tissue, at least some of the cut tissue is captured in a hollow interior portion of elongate body 108. Various embodiments may further include a cover, a cut tissue housing portion and/or the like for collecting cut tissue and/or other tissue debris. Such collected tissue and debris may then be removed from the patient during or after a tissue modification procedure. During a given tissue modification procedure, distal blade 110a may be drawn proximally to cut tissue, allowed to retract distally, and drawn proximally again to further cut tissue as many times as desired to achieve a desired amount of tissue cutting.

Blades 110 may be made from any suitable metal, polymer, ceramic, or combination thereof. Suitable metals, for example, may include but are not limited to stainless steel (303, 304, 316, 316L), nickel-titanium alloy, tungsten carbide alloy, or cobalt-chromium alloy, for example, Elgiloy® (Elgin Specialty Metals, Elgin, Ill., USA), Conichrome® (Carpenter Technology, Reading, Pa., USA), or Phynox® (Imphy SA, Paris, France). In some embodiments, materials for the blades or for portions or coatings of the blades may be chosen for their electrically conductive or thermally resistive properties. Suitable polymers include but are not limited to nylon, polyester, Dacron®, polyethylene, acetal, Delrin® (DuPont, Wilmington, Del.), polycarbonate, nylon, polyetheretherketone (PEEK), and polyetherketoneketone (PEKK). In some embodiments, polymers may be glass-filled to add strength and stiffness. Ceramics may include but are not limited to aluminas, zirconias, and carbides. In various embodiments, blades 110 may be manufactured using metal injection molding (MIM), CNC machining, injection molding, grinding and/or the like. Pull wires 118 be made from metal or polymer and may have circular, oval, rectangular, square or braided cross-sections. In some embodiments, a diameter of a pull wire 118 may range from about 0.001″-0.050″, and more preferably from about 0.010″-0.020″.

Depending on the tissue to be treated or modified, activating blades 110 (or other tissue modifying members in alternative embodiments) may cause them to modify target tissue along an area having any of a number of suitable lengths. In use, it may also be advantageous to limit the extent of action of blades 110 or other tissue modifying members to a desired length of tissue, thus not allowing blades 110 to affect tissue beyond that length. In so limiting the effect of blades, unwanted modification of, or damage to, surrounding tissues and structures may be limited or even eliminated. In one embodiment, for example, where the tissue modification device is used to modify tissue in a spine, blades 110 may operate along a length of target tissue of no more than 10 cm, and preferably no more than 6 cm, and even more preferably no more than 3 cm. Of course, in other parts of the body and to address other tissues, different tissue modification devices may be used and tissue modifying members may have many different lengths of activity. In one embodiment, to facilitate proper location of tissue modifying members, such as blades 110, relative to target tissue, the tissue modifying members and/or the elongate body and/or one or more additional features intended for just such a purpose may be composed of a material readily identifiable via x-ray, fluoroscopic, magnetic resonance or ultrasound imaging techniques.

In various embodiments, a number of different techniques may be used to prevent blades 110 (or other tissue modifying members) from extending significantly beyond the target tissue. In one embodiment, for example, preventing blades 110 from extending significantly beyond the target tissue involves holding tissue modification device 102 as a whole predominantly stable to prevent device 102 from translating in a direction toward its proximal portion or toward its distal portion while activating blades 110. Holding device 102 stable is achieved by anchoring one end of the device and applying tensioning force at or near the other end, as described further below.

In the embodiment shown in FIGS. 3A-3I, pull wires 118 are retracted proximally by squeezing actuator 106 proximally. In an alternative embodiment, squeezing actuator 106 may cause both blades 110 to translate inward so that they meet approximately in the middle of window 111. In a further embodiment, distal blade 110a may be returned to it's starting position by a pulling force generated from the distal end of device 102, for example by using a distal actuator that is attached to distal wires, or by pulling on the distal guide member which is attached to distal blade 110a. In yet another alternative embodiment, proximal blade 110b may be moved to cut by a pulling force generated from the distal end of device 102, for example by using a distal actuator that is attached to distal wires, or by pulling on the distal guide member which is attached to proximal blade 110b. In yet another embodiment, squeezing actuator 106 may cause proximal blade 110b to move distally while distal blade 110a stays fixed. In other alternative embodiments, one or more blades 110 may move side-to-side, one or more blades 110 may pop, slide or bow up out of window 111 when activated, or one or more blades 110 may expand through window. In another embodiment, one or more blades 110 and/or other tissue modifying members of device 102 may be powered devices configured to cut, shave, grind, abrade and/or resect target tissue. In other embodiments, one or more blades may be coupled with an energy transmission device, such as a radiofrequency (RF) or thermal resistive device, to provide energy to blade(s) 110 for cutting, ablating, shrinking, dissecting, coagulating or heating and thus enhancing tissue modification. In another embodiment, a rasp or file may be used in conjunction with or coupled with one or more blades. In any of these embodiments, use of actuator 106 and one or more moving blades 110 provides for tissue modification with relatively little overall translation or other movement of tissue modification device 102. Thus, target tissue may be modified without extending blades 110 or other tissue modification members significantly beyond an area of target tissue to be treated.

Referring now to FIGS. 4A-4C, in an alternative embodiment, a tissue modification device 202 may include an elongate body 208 having a proximal portion and a distal portion 209, a handle 204 and actuator 206 coupled with proximal portion, and a window 211 and tissue modifying member 210 disposed near distal portion 209. As seen more clearly in FIGS. 4B and 4C, in the embodiment shown, tissue modifying member 210 comprises an RF electrode wire loop. Wire loop 210 may comprise any suitable RF electrode, such as those commonly used and known in the electrosurgical arts, and may be powered by an internal or external RF generator, such as the RF generators provided by Gyrus Medical, Inc. (Maple Grove, Minn.). Any of a number of different ranges of radio frequency may be used, according to various embodiments. For example, some embodiments may use RF energy in a range of between about 70 hertz and about 5 megahertz. In some embodiments, the power range for RF energy may be between about 0.5 Watts and about 200 Watts. Additionally, in various embodiments, RF current may be delivered directly into conductive tissue or may be delivered to a conductive medium, such as saline or Lactate Ringers solution, which may in some embodiments be heated or vaporized or converted to plasma that in turn modifies target tissue. Distal portion 209 includes a tapered tip, similar to that described above, to facilitate passage of elongate body 208 into narrow anatomical sites. Handle 204 and actuator 206 are similar to those described above, although in the embodiment of FIGS. 4A-4C, actuator 206 may be used to change the diameter of the wire loop 210. Using actuator 206, wire loop 210 may be caused to extend out of window 211, expand, retract, translate and/or the like. Some embodiments may optionally include a second actuator (not shown), such as a foot switch for activating an RF generator to delivery RF current to an electrode.

Elongate body 208 may be fabricated from any suitable material and have any of a number of configurations. In one embodiment, body 208 comprises a metal tube with a full-thickness slit (to unfold the tube into a flat form—not shown) or stiffening element (not shown). The split tube provides for a simple manufacturing process as well as a conductive pathway for bi-polar RF operation.

Referring to FIG. 4C, insulators 222 may be disposed around a portion of wire loop 210 so that only a desired portion of wire loop 210 may transfer RF current into the tissue for tissue modifying capability. Wire loop 210, covered with insulators 222 may extend proximally into support tubes 218. In various alternative embodiments, an electrode tissue modifying member (of which wire loop 210 is but one example) may be bipolar or monopolar. For example, as shown in FIG. 4C, a sleeve 224 housed toward the distal portion of window 211 may act as a return electrode for wire loop 210 in a bipolar device. Wire loop electrodes 210 may be made from various conductive metals such as stainless steel alloys, nickel titanium alloys, titanium alloys, tungsten alloys and the like. Insulators 222 may be made from a thermally and electrically stable polymer, such as polyimide, polyetheretherketone (PEEK), polytetrafluoroethylene (PTFE), polyamide-imide, or the like, and may optionally be fiber reinforced or contain a braid for additional stiffness and strength. In alternative embodiments, insulators 222 may be composed of a ceramic-based material.

In one embodiment, wire loop 210 may be housed within elongate body 208 during delivery of tissue modification device 202 into a patient, and then caused to extend up out of window 211, relative to the rest of body 208, to remove tissue. Wire loop 210 may also be flexible so that it may pop or bow up out of window 211 and may deflect when it encounters hard tissue surfaces. Wire loop 210 may have any of a number of shapes, such as curved, flat, spiral or ridged. Wire loop 210 may have a diameter similar to the width of body 208, while in alternative embodiments it may expand when extended out of window 211 to have a smaller or larger diameter than that of body 208. Pull wires (not shown) may be retracted proximally, in a manner similar to that described above, in order to collapse wire loop 210, decrease the diameter and lower the profile of the wire loop 210, and/or pull wire loop 210 proximally to remove tissue or be housed within body 208. The low profile of the collapsed wire loop 210, facilitates insertion and removal of tissue modification device 202 prior to and after tissue modification. As the wire loop 210 diameter is reduced, support tubes 218 deflect toward the center of elongate body 208.

In an alternative embodiment (not shown), tissue modification device 202 may include multiple RF wire loops 210 or other RF members. In another embodiment, device 202 may include one or more blades as well as RF wire loop 210. In such an embodiment, wire loop 210 may be used to remove or otherwise modify soft tissues, such as ligamentum flavum, or to provide hemostasis, and blades may be used to modify hard tissues, such as bone. In other embodiments, as described further below, two separate tissue modification devices (or more than two devices) may be used in one procedure to modify different types of tissue, enhance modification of one type of tissue or the like.

In other alternative embodiments, tissue modification devices 202 may include tissue modifying members such as a rongeur, a curette, a scalpel, a scissors, a forceps, a probe, a rasp, a file, an abrasive element, one or more small planes, a rotary powered mechanical shaver, a reciprocating powered mechanical shaver, a powered mechanical burr, a laser, an ultrasound crystal a cryogenic probe, a pressurized water jet, a drug dispensing element, a needle, a needle electrode, or some combination thereof. In some embodiments, for example, it may be advantageous to have one or more tissue modifying members that stabilize target tissue, such as by grasping the tissue or using tissue restraints such as barbs, hooks, compressive members or the like. In one embodiment, soft tissue may be stabilized by applying a contained, low-temperature substance (for example, in the cryo-range of temperatures) that hardens the tissue, thus facilitating resection of the tissue by a blade, rasp or other device. In another embodiment, one or more stiffening substances or members may be applied to tissue, such as bioabsorbable rods.

Referring now to FIGS. 5A-5D, one embodiment of a method for modifying tissue in a spine is demonstrated in simplified, diagrammatic, cross-sectional views of a portion of a patient's back and spine. FIG. 5A shows a portion of the patient's back in cross section, with a portion of a vertebra, the spinal cord with branching nerve roots, and target tissue, which in this illustration is the ligamentum flavum and possibly a portion of the facet capsule. The target tissue is typically impinging directly on one or more of the group including nerve roots, neurovascular structures, dorsal root ganglia, cauda equina, or individual nerves.

In FIG. 5B, tissue modification device 102 has been positioned in the patient's back to perform a tissue modification procedure. Various methods, devices and systems for introducing device 102 into the patient and advancing it to the position for modifying tissue are described in further detail below. Generally, device 102 may be positioned via a percutaneous or open surgical procedure, according to various embodiments. In one embodiment, device 102 may be inserted into the patient through a first incision 240, advanced into the spine and between target tissue and non-target tissue (such as spinal cord, nerve roots, nerves and/or neurovascular tissue), and further advanced so a distal portion of elongate body 108 exits a second (or distal) incision or non-incision exit point 242 to reside outside the patient. In positioning device 102, one or more tissue modifying members (not shown) are positioned to face the target tissue, while one or more protective portions of elongate body 108 face non-target tissue.

Referring to FIG. 5C, once device 102 is positioned in a desired location, anchoring force may be applied at or near the distal portion of elongate body 108. In one embodiment, applying anchoring force involves a user 244 grasping body 108 at or near its distal portion. In alternative embodiments, as described further below, anchoring force may be applied by deploying one or more anchor members disposed at or near the distal portion of body 108, or by grasping a guidewire or other guide member coupled with or extending through at least part of body 108, in some cases using a distal handle (not shown). Once the anchoring force is applied, proximally-directed tensioning force may be applied to device 102, such as by pulling proximally on proximal handle 104 (one-directional, diagonal arrows). This tensioning force, when applied to the substantially anchored device 102, may help urge the tissue modifying member(s) against the target tissue (one-directional, vertical arrows near target tissue), thus enhancing contact with the target tissue and facilitating its modification. Of course, in this or other embodiments, as mentioned above, any combination of tensioning and/or anchoring forces may be applied to proximal and distal portions of tissue modification device 102, either in different procedures or during the same procedure. With the tissue modifying member(s) contacting the target tissue, actuator 106 may be squeezed or pulled (two-headed arrow) to cause the tissue modifying member(s) to modify tissue. (Alternative actuators may be activated in different ways in alternative embodiments.)

In various alternative embodiments, certain of the above-described steps may be carried out in different order. For example, in one embodiment the distal portion of elongate body 108 may be anchored within or outside the patient before the tissue modifying members are positioned adjacent the target tissue. In another alternative embodiment, the proximal portion of device 102 may be anchored, and the tensioning force may be applied to the distal portion of device 102. In yet another embodiment, tensioning force may be applied to both ends of the device. In yet another embodiment, a second handle and actuator may be coupled with the distal end of body 108 after it exits the patient's back, allowing tensioning forces as well as tissue modifying actuation to occur at both the proximal and distal portions of device 102. By anchoring one end of device 102 and applying tensioning force to the opposite end, contact of the tissue modifying members with the target tissue is enhanced, thus reducing or eliminating the need for translating or otherwise moving device 102 as a whole and reducing the overall profile and the resulting access pathway required to position the device. Reducing movement and profile of device 102 and using tissue modifying members confined to a relatively small area of device 102 helps facilitate target tissue modification while minimizing or eliminating damage to surrounding tissues or structures.

As mentioned above, tissue may be modified using one tissue modification device or multiple devices, according to various embodiments. In one embodiment, for example, an RF electrosurgical tissue modification device may be used in the patient to remove soft tissue such as ligament, and a bladed tissue modification device such as a rongeur may then be used to remove additional soft tissue, calcified soft tissue, or hard tissue such as bone. In some embodiments, such multiple devices may be inserted, used and removed serially, while in alternative embodiments such devices may be inserted into the patient at the same time to be used in combination.

Referring to FIG. 5D, using one or more tissue modification devices 102, a desired amount of target tissue may be removed from more than one area in the spine. FIGS. 5A-5C demonstrate removal of target tissue on one side of the spine, and that method or a similar method may also be used to remove target tissue on an opposite side of the spine, as shown in FIG. 5D, where target tissue has been removed from both sides. That the desired amount of tissue has been removed may be confirmed by tactile feedback from the device or from a separate device, by testing nerve conduction through one or more previously impinged nerves, by testing blood flow through one or more previously impinged blood vessels, by passing (independently or over the guide member) a measurement probe or sound through the treated portion, through one or more radiographic tests, through some combination thereof, or by any other reasonable means.

Referring now to FIG. 6A, tissue modification device 102 is shown with one embodiment of a distal anchoring member 250 deployed at the patient's skin. In various embodiments, anchoring members may include but are not limited to one or more handles, barbs, hooks, screws, toggle bolts, needles, inflatable balloons, meshes, stents, wires, lassos, backstops or the like. In some embodiments, anchoring members 250 may be disposed at the extreme distal portion 109 of elongate body 108, while in other embodiments anchoring members 250 may be located more proximally. In the embodiment shown, anchoring members 250 are deployed at the patient's skin. In an alternative embodiment, anchoring may be achieved outside the patient by deploying one or more anchoring members 250 above the skin and having a user grasp the anchoring members 250. In an alternative embodiment, anchoring may be achieved outside the patient by deploying one or more anchoring members 250 above the skin and having a user grasp anchoring members 250, after tissue modification device 102 has been anchored to the guide member. In another alternative embodiment, anchoring may be achieved outside the patient by attaching anchoring member 250 to an external device, for example one that is mounted on the patient or on the procedure table. In a further alternative embodiment, anchoring may be achieved outside the patient by attaching the guide member to an external device, for example one that is mounted to on the patient or on the procedure table, after tissue modification device 102 has been anchored to the guide member. Anchoring members 250 generally are deployable from a first, contracted configuration to facilitate delivery of device 102, to a second, expanded configuration to facilitate anchoring. This change in configuration may be achieved, for example, by using shape memory or super-elastic materials, by spring loading anchoring members 250 into body 108 or the like. In most embodiments, anchoring members 250 may also be collapsed down into the first, contracted configuration after a tissue modification procedure has been performed, to facilitate withdrawal of device 102 from the patient. In an alternative embodiment, anchoring members 250 may detach from body 108 and may be easily removable from the patient's skin.

FIG. 6B shows tissue modification device 102 with an alternative embodiment of a distal anchoring member 260. Here, distal anchoring member 260 includes multiple hooks or barbs extended out the distal portion 109 of elongate body 108 within the patient's back. In using such an embodiment, it may not be necessary to pass guide member 117 through a second, distal incision on the patient, although in some embodiments guide member 117 may extend significantly beyond distal portion 109. Anchoring member(s) 260, according to various embodiments, may be deployed so as to anchor to bone, ligament, tendon, capsule, cartilage, muscle, or any other suitable tissue of the patient. They may be deployed into vertebral bone or other suitable tissue immediately adjacent an intervertebral foramen or at a location more distant from the intervertebral foramen. When a tissue modification procedure is complete, anchoring members 260 are retracted within elongate body for removal of device 102 from the patient.

Referring now to FIGS. 7A-7S, a system and method for introducing a tissue modification device into a spine is demonstrated. This system and method may be referred to as an “access system” or “access method,” in that they provide or facilitate gaining access to a target tissue to be modified. Of course, the embodiment shown is merely one exemplary embodiment, and any of a number of other suitable methods, devices or systems may be used to introduce one or more devices for modifying tissue in spine. For example, in one alternative embodiment, a spinal tissue modification procedure may be carried out through an open surgical approach. Therefore, the following description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is defined in the claims.

Referring to FIG. 7A, in one embodiment a device delivery method first involves advancing an introducer cannula 300 coupled with a stylet 302 into the patient's back. Cannula 300 and stylet 302 are then passed between adjacent vertebrae and into the ligamentum flavum or an adjacent spinal ligament, as shown further in FIG. 7B. As shown in FIG. 7C, when the distal tip of cannula is positioned as desired, stylet 302 is removed. Referring to FIGS. 7D and 7E, a loss of resistance syringe 304 including a plunger 310, barrel 308 and fluid and/or air 306, is coupled with the proximal portion of cannula 300. The distal portion of cannula 300 is advanced through the ligamentum flavum until it enters the central spinal canal where a loss of resistance to pressure placed on plunger 310 is encountered, and fluid and/or air 306 is injected into central spinal canal to confirm correct placement of cannula 300 as shown in FIG. 7E. Syringe 304 is then removed, as in FIG. 7F, and a guidewire 312 with a non-rigid, atraumatic tip is advanced through cannula 300 into the central spinal canal, as in FIG. 7G. Next, cannula 300 is removed, as in FIG. 7H, leaving behind guidewire 312. As shown in FIGS. 7I and 7J, an introducer sheath 114, coupled with a dilator 314, is then advanced over guidewire 312 to position a distal portion of sheath 114 at a desired location within the spine. Dilator 314 and guidewire 312 are then removed, as in FIG. 7K.

Once introducer sheath 114 is in place, one or more curved or steerable guide devices 318 may be advanced through it to desired positions in and/or through the spine, as shown in FIGS. 7L and 7M. One or more guide members 116, may then be advanced through guide device 318, as shown in FIGS. 7N-7P. In some embodiments, guide member 116 may comprise a guidewire having a beveled tip 117 to facilitate passage of guidewire 116 through tissue (FIG. 7O). Also in some embodiments, passing guidewire 116 through guide device 318 may partially straighten the distal portion of guide device 318. Finally, guide device 318 may be removed, as in FIG. 7Q, and elongate body 108 of tissue modification device 102 may be advanced over guide member 116 and through introducer sheath 114 to a desired position in the spine, as in FIG. 7R. In an alternative embodiment, guidewire 116 may be coupled with tissue modification device 102 at or near its distal end and used to pull tissue modification device 102 into a desired position. As shown in FIG. 7S, elongate body 108 may be tensioned to urge tissue modifying members 110 against target tissue, as shown with arrows at opposite ends of device 102, while distal portion 109 is anchored, in this case by hand 244. In an alternative embodiment, guide member 116 may be tensioned to urge tissue modifying members 110 against target tissue as shown in FIG. 7R.

Once tissue modification device 102 is in a desired position, tissues which may be modified in various embodiments include, but are not limited to, ligament, tendon, tumor, cyst, cartilage, scar, “bone spurs,” inflammatory and bone tissue. In some embodiments, modifying the target tissue reduces impingement of the tissue on a spinal cord, a branching nerve or nerve root, a dorsal root ganglia, and/or vascular tissue in the spine. Actuator 106 on handle 104 may be activated to modify target tissue using tissue modification member(s) 110, while elongate body 108 may be held relatively stable by hand 244 and by tension force applied to handle 104.

In various embodiments, the system and method described immediately above may include additional features or steps, may have fewer features or steps, may have an alternate order of implementation of steps, or may have different features or steps. For example, in some embodiments placement of device 102 will be performed in a medial-to-lateral direction (relative to the patient), while in alternative embodiments device placement will be performed lateral-to-medial. In some embodiments, one or more components of the system described may be anchored to the patient, such as guide member 116 or introducer sheath 114. In various embodiments, one or more guide members 116 may include one or more wires, rails or tracks and may be inserted through guide device 318, introducer sheath 114 without guide device 318, cannula 300, an epidural needle, a lumen of an endoscope, a lumen of a tissue shield or barrier device, a curved guide device 318 placed through a lumen of an endoscope, or the like. In other embodiments, for example, guide device 318 may be placed through introducer cannula 300 and then introducer sheath 114 may be passed over guide device 318. Tissue modification device 102 may similarly be inserted with or without using any of these devices or components in various combinations. Various guidewires 312, guide devices 318 and/or guide members 116 may be pre-shaped to have one or more curves, may be steerable, and/or may include one or more rails, tracks, grooves, lumens, slots, partial lumens, or some combination thereof.

In some embodiments, tissue modification device 102 may be inserted through one or more hollow devices as described above (such as introducer sheath 114, as shown, or cannula 300 in an alternative embodiment) in such a way that device 102 expands upon extending out of a distal portion of the hollow delivery device, thereby assuming a wider profile for modifying a greater amount of target tissue from a single location. In an alternative embodiment, device 102 may retain the same overall profile during insertion and during use. In some embodiments, one or more delivery devices may remain in the patient during use of tissue modification device 102, while in alternative embodiments, all delivery devices may be removed from the patient when tissue modification device 102 is operating. In some embodiments, tissue modification device 102 may be slidably coupled with one or more delivery devices during delivery and/or during use. In one embodiment, tissue modification device 102 may be advanced through introducer sheath 114, and sheath 114 may be used as an irrigation and evacuation lumen to irrigate the area of the target tissue and evacuate removed tissue and other debris, typically by applying a vacuum. In alternative embodiments, tissue modification device 102 may include an irrigation and/or evacuation lumen to irrigate an area of the target tissue and evacuate removed tissue and other debris.

Some embodiments of an access system for facilitating tissue modification may further include one or more visualization devices (not shown). Such devices may be used to facilitate placement of the access system for introducing the tissue modification device, to facilitate tissue modification itself, or any combination of these functions. Examples of visualization devices that may be used include flexible, partially flexible, or rigid fiber optic scopes, rigid rod and lens endoscopes, CCD (charge-coupled device) or CMOS (complementary metal-oxide semiconductor) chips at the distal portion of rigid or flexible probes, LED illumination, fibers or transmission of an external light source for illumination or the like. Such devices may be slidably couplable with one or more components of an access system or may be slidably or fixedly coupled with a tissue modification device. In other embodiments, additional or alternative devices for helping position, use or assess the effect of a tissue modification device may be included. Examples of other such devices may include one or more neural stimulation electrodes with EMG or SSEP monitoring, ultrasound imaging transducers external or internal to the patient, a computed tomography (CT) scanner, a magnetic resonance imaging (MRI) scanner, a reflectance spectrophotometry device, and a tissue impedance monitor disposed across a bipolar electrode tissue modification member or disposed elsewhere on a tissue modification device or disposed on the access system.

Referring now to FIGS. 8A-8E, in an alternative embodiment, a tissue modification device and optionally one or more introduction/access devices may be positioned in a patient using an open surgical technique. As shown in FIG. 8A, for example, in one embodiment an open surgical incision is made on a patient's back, and two retractors 402 are used to expose a portion of the patient's vertebra. As shown in FIG. 8B, an introducer sheath 414 may then be inserted through the incision, between retractors 402. As in FIG. 8C, a curved guide device 418 may then be inserted through introducer sheath 414. Guide device 418 extends into the epidural space and through the intervertebral foramen as shown in FIG. 8D.

In some embodiments, a curved and cannulated thin, blunt probe may be placed directly through the open incision into the epidural space of the spine, or alternatively may be placed through introducer sheath 414. The probe tip may be advanced to or through a neural foramen. Such a probe may be similar in shape, for example, to a Woodson elevator, Penfield 3, hockey stick probe, ball tipped probe, or the like. In alternative embodiments, probes that may be manually bent to change their shapes, or probes with articulating tips, or probes with shape lock portions, and/or probes having grooves instead of cannulas may be used.

As shown in FIGS. 8D-8E, a substantially straight, flexible guidewire 420 with a sharp tip 422 may then be inserted through curved guide device 418 and advanced so that its distal portion with sharp tip 422 extends outside the patient's back at a location separate from the open incision (FIG. 8E). Guide device 418 may then be removed, as in FIG. 8F, and in subsequent steps a tissue modification device may be inserted over guide wire 420 and through introducer sheath 414 and used to modify tissue as described in more detail above. In an alternative embodiment, a curved, flexible cannula may be inserted through the curved guide device, until it extends lateral to the neural foramen, after which a substantially straight, flexible guidewire with a sharp tip may then be inserted through curved cannula and advanced so that its distal portion with sharp tip extends outside the patient's back.

Referring now to FIGS. 9A and 9B, another alternative open surgical access method is shown. In FIG. 9A, a curved guide device 446 is shown in place through the epidural space and intervertebral foramen, and a guidewire 440 with a beveled distal tip 442 is about to be advanced through guide device 446. As shown in FIG. 9B, in this embodiment, guidewire 440 is directed by guide device 446 back through the open incision through which the various access devices are introduced. In such an embodiment, then, only one incision is created and the proximal and distal portions of one or more devices extend out of the patient's back through the same incision.

In various alternative embodiments, open surgical access may be through exposure down to a vertebral lamina, through ligamentum flavum without lamina removal, through ligamentum flavum with partial or complete lamina removal, through ligamentum flavum with or without lamina removal with partial or complete medial facet joint removal, through open exposure and out through skin laterally, through open exposure and back out through the open exposure, or through a lateral open exposure that accesses the neural foramen from the lateral side. One or more visualization devices may be used with open surgical access procedures as well as with percutaneous or other less invasive procedures. In another alternative embodiment (not shown), a tissue modification device may be placed in the patient directly, without any introduction devices.

With reference to FIGS. 10A-10F, an alternative method and apparatus for obtaining access to the neural foramen utilizing an open surgical approach are described. Similar methods and apparatus are described in U.S. patent application Ser. Nos. 11/251,205 (FIGS. 26-27 and accompanying description) and 60/681,719, which were previously incorporated by reference. FIGS. 10A and 10B illustrate two alternative embodiments of an access device 84, 85. In one embodiment (FIG. 10A), access device 84 may comprise a cannulated probe 86, illustratively an elevator probe having a first lumen 88 and a second lumen 90. In one embodiment, a visualization element 92, such as an epidural endoscope, may be advanced through or coupled to first lumen 88 (or alternatively second lumen 90) to provide visualization at the distal tip of probe 86.

In an alternative embodiment (FIG. 10B), an access device 85 may comprises a probe 87 and a single lumen 89. Visualization device 92, as well as a cannula 94 or curved guidewire (shown in later figures), may be advanced through lumen 89, either in parallel or in sequence. Alternatively, visualization device 92 may be omitted or may be attached directly to probe 87. In various embodiments, access device 84, 85 may comprise any desired number of lumens 88, 89, 92.

In one embodiment, and with reference now to FIG. 10C, the dual lumen embodiment of access device 84 may be passed through a surgical incision or cut-down to position its distal end in proximity to an intervertebral (or “neural”) foramen while under optional visualization via visualization device 92. Visualization may facilitate access via a minimally invasive or keyhole surgical cut-down and may also facilitate a fully open approach. Direct visualization alternatively or additionally may be utilized. In some embodiments, as described in greater detail below, probe 86 may include one or more electrodes at or near upper and/or lower surfaces of its distal end. Such electrodes may be used to test for proper placement of probe 86 above the nerve root and/or cauda equine or spinal cord.

As seen in FIG. 10D, with probe 86 properly positioned, an atraumatic curved tube, introducer or cannula 94 may be advanced through either lumen 88, 90 of probe 86 and driven laterally to cannulate the intervertebral foramen. In some embodiments, visualization device 92 may be removed from probe 86, as shown in FIG. 10D, while in other embodiments device 92 may remain in one of lumens 88, 90. Cannula 94 optionally may be configured to deliver a stimulation waveform at or near its distal tip for monitoring proximity to the nerve root during cannulation of the foramina with the cannula.

As seen in FIG. 10E, once access device 84 is in a desired location, in one embodiment a straight, flexible guidewire 4 or needle, which optionally comprises a sharpened tip, may be advanced through cannula 94 and driven posteriorly through the skin of the patient's back. Alternatively, a second surgical incision and or cut-down may be formed at or near the exit of the intervertbral foramen for grasping guidewire 4 and pulling it through. As shown in FIG. 10F, with access guidewire 4 positioned through and across the intervertebral foramen, probe 86 may be removed. This leaves guidewire 4 in place to provide access for any other suitable device or devices, such as a tissue modification device.

With reference now to FIGS. 11A-11E, an alternative embodiment of a spinal access method and device, similar to that described in FIGS. 10A-10F, is shown. (FIGS. 11A-11E are not drawn to scale.) In one embodiment, a probe 602 may be inserted into a patient's back via an open surgical approach using retractors 612, although less invasive (“partial open”) or percutaneous access approaches may be employed in alternative embodiments. Probe 602 may include an elongate shaft 604 (or “body”) having a longitudinal axis, a distal portion with a flat configuration having an upper surface 606 and an opposed lower surface 607, and an inner lumen. Probe 602 may also include a flexible, tubular guide member slidably disposed in the lumen of shaft 604 (lumen and guide member not shown in FIG. 11A) and a slide member 608 coupled with shaft 604 and the guide member. Optionally, some embodiments may also include one or more electrodes (or “signal transmitters”) or energy modulated members coupled with upper surface 606 and/or lower surface 607. In FIGS. 11A-11C, the electrodes/signal transmitters are not visible, because they are embedded in upper surface 606 and lower surface 607.

Electrodes coupled with upper and lower surfaces 606, 607 may be coupled proximally with wires 610, which extend along the length of shaft 604 and then extend to a signal source 618 (or “power source”). In an alternative embodiment, probe 602 may include an internal power source, such as a battery housed in or coupled with shaft 604. Signal source 618 may, in some embodiments, be coupled with one or more electromyograhpy (EMG) electrodes 619. EMG electrodes 619 generally comprise electrodes capable of detecting an EMG response and are configured to be inserted into a muscle physiologically coupled to a nerve to be monitored or placed on skin above the muscle. Signal source 618 may be configured to receive sensed EMG signals from EMG electrodes 619 and process such signals to provide data to a user. In such systems, a display monitor may optionally be included, either as a separate unit or as part of signal source 618. Any suitable number of EMG electrodes 619 may be coupled with signal source 618, in various embodiments, and the two EMG electrodes 619 shown are for exemplary purposes only. For example, in some embodiments, such as when a lumbar spinal stenosis treatment is to be performed, EMG electrodes 619 may be placed bilaterally in a patient's tibialis anterior, vastus medialis, biceps femoris and medial gastroc muscles, or some combination thereof. In alternative embodiments, other nerve monitoring or sensing technologies may be used instead of or in addition to EMG, such as somatosensory evoked potentials (SSEPs), motor evoked potentials (MEPs), or the like. Additionally or alternatively, visible and/or palpable muscle twitch may be monitored in any embodiment.

As shown in FIG. 11A, probe 602 may be advanced along a natural tissue interface between neural tissue (cauda equina or spinal cord and nerve root, for example) and another tissue (or tissues) in the body, such as ligamentum flavum and/or vertebral bone, such as superior and inferior articular processes of a facet joint. In other words, probe 602 may be advanced along this tissue interface such that lower surface 607 is oriented toward the neural tissue and upper surface 606 is oriented away from the neural tissue. In some embodiments, the distal portion of shaft 604 may be advanced to position upper surface 606 and lower surface 607 partially or completely within an intervertebral foramen. In some embodiments, the tissue interface comprises two adjacent tissue planes, and advancing probe 602 may cause the distal end of probe 602 to dissect neural tissue from other tissue, such as target ligament and/or bone tissue, along the tissue interface. Generally, probe 602 may be advanced along a path approximating a path along which a tissue removal or modification device may be passed.

In some cases, the distal portion of shaft 604 may be positioned between neural and non-neural tissue without the surgeon being able to view the positioning. In other embodiments, it may be possible to visualize placement of shaft 604 using one or more visualization devices, such as externally applied fluoroscopy or a visualization device coupled with probe 602. In some embodiments, a surgeon or other physician placing probe 602 between two tissues will typically want to confirm that a desired positioning of probe 602 relative to the tissues has been achieved. For example, a surgeon may want to confirm that the distal portion of probe 602 has not been placed under the nerve root rather than between the nerve root and target tissue. In some embodiments, confirming a desired placement of probe 602 may involve delivering a first electrical current to a first electrode along lower surface 607, delivering a second electrical current to a second electrode along upper surface 606, and verifying that lower surface 607 of the advanced probe 602 remains oriented toward the neural tissue and upper surface 606 remains oriented away from the neural tissue by monitoring neural response (e.g., action potentials) to the first and second electrical currents. In an alternative method, the order of delivering current may be switched, so that the electrode on the upper surface 606 is activated before the electrode on the lower surface 607.

In some embodiments, electrical current may be applied to either electrode, and the current may be increased (if necessary) until a response in nearby nerve tissue is measurable, such as by EMG measurements, and/or observable, such as by viewing or feeling a muscle twitch. It has been found that even when an electrode on an upper surface 606 of probe 602 is located adjacent non-neural tissue, the electrode will eventually stimulate a nearby nerve if the current is increased to a sufficient level. It has also been found that an electrode located on a surface 606, 607 immediately adjacent or in direct contact with neural tissue requires significantly less current to stimulate a nerve response than the current required in the electrode farther from the nerve. Thus, in one embodiment, sufficient current may be applied to an electrode on upper surface 606 to stimulate neural tissue, sufficient current may be applied to an electrode on lower surface 607 to stimulate neural tissue, and the amounts of current required for each electrode (“threshold currents”) may be compared, to determine which surface 606, 607 is closest to the nerve, nerve root, cauda equina and/or spinal cord. In this way, the location of neural tissue relative to probe 602 may be determined, thus facilitating safe placement and orientation of a guidewire, and subsequently a tissue modification device, between target and non-target tissues. This is just one example of a method for locating neural tissue. Further description of optional energy-delivery members and various neural localization methods are described further below, and as mentioned earlier, neural localization is an optional feature.

Referring to FIG. 11B, with the distal portion of probe 602 in place between target and non-target tissue, slide 608 may be advanced toward the distal end of probe 602 (solid-tipped arrow), to push a flexible, hollow, curved guide member 614 out of a distal opening in the lumen within probe 602 (hollow-tipped arrow). Curved guide member 614 may be housed within the lumen (not shown) in probe 602 during placement/positioning of probe 602 and may then be advanced, as shown in FIG. 11B. In one embodiment, guide member 614 may be hollow and tubular, with one central lumen running longitudinally through it. In alternative embodiments, guide member 614 may have multiple lumens and/or have an alternative cross-sectional shape, such as but not limited to flat/hollow, ovoid, elliptical, rectangular, figure-8 or the like. In various embodiments, curved guide member 614 may be made of any of a number of different materials, may have a variety of different lengths, diameters and wall thicknesses, and may have any of a variety of different radii of curvature. For example, in various alternative embodiments, curved guide member 614 may be made of a metal, a polymer, such as nylon, polyester, Dacron®, polyethylene, acetal, Delrin® (DuPont, Wilmington, Del.), polycarbonate, nylon, polyetheretherketone (PEEK), and polyetherketoneketone (PEKK), or some combination of polymers or metals and polymers.

In various embodiments, curved guide member 614 may extend out of the distal opening on probe for any desired length, such as between about 1 mm and about 5 cm. In some embodiments, guide member 614 may have a first shape (such as predominantly straight) while residing within the lumen in probe 602 and may assume a second, curved shape upon exiting the distal opening. To allow for such a shape change, in some embodiments, guide member 614 may be fabricated, at least in part, of shape memory or super-elastic materials. In alternative embodiments, guide member 614 may assume a straight configuration upon exiting the distal opening in probe 602. For example, in one embodiment, the distal portion of probe 602 may be curved, and guide member 614 may exit the distal opening and proceed in approximately a straight line from the distal opening. In various curved embodiments, guide member 614 may have any suitable radius of curvature. In one embodiment (shown in FIG. 11B), guide member 614 may be configured to curve around a surface of a facet joint between two vertebrae. In alternative embodiments, rather than (or in addition to) activating one or more electrodes on one or more surfaces of the distal portion of probe 602, such electrodes may be disposed on one or more surfaces of guide member 614. Examples of such embodiments are described further below.

As shown in FIG. 11C, after guide member 614 has been advanced at least partially out of the distal opening in probe 602, a guidewire 616 may be advanced into probe 602 (solid-tipped arrow) and through guide member 614 to pass through the patient's tissue and out the back (hollow-tipped arrow). In one embodiment, probe 602 includes an inner lumen that is continuous from a proximal opening, into which guidewire may be inserted, through to a distal opening, through which guide member 614 is advanced. Guidewire 616 thus may be advanced into the lumen of probe 602, into a proximal opening of a lumen of guide member 614, which resides in the probe lumen, and out of a distal opening of the lumen of guide member 614. Generally, guide member 614 helps direct guidewire 616 out of the patient's back in approximately a desired direction. In some embodiments, guide member 614 may be sufficiently rigid that passing guidewire 616 through guide member 614 will not significantly change the radius of curvature of guide member 614. In an alternative embodiment, guide member 614 may be more flexible, such that guidewire 616 may at least partially straighten guide member 614 when it passes through its lumen. In some embodiments, guide member 614 may be shaped to direct guidewire 616 out of the patient's back at a location apart from the entry point of probe 602 into the back (as shown in FIG. 11C), while in alternative embodiments, guide member 614 may have a smaller radius of curvature and/or may be less flexible, to direct guidewire 616 out of the patient's back at a location at or near the entry point of probe 602 into the back. Guidewire 616 may have a beveled or sharpened distal tip to facilitate its passage through tissue in the back, the skin or elsewhere.

Once guidewire 616 is in a desired location in the patient, probe 602 may be removed from the patient. In one embodiment, guide member 614 may be retracted back into shaft 604 before probe 602 is withdrawn from the patient, while in alternative embodiments, probe 602 may be withdrawn without retracting guide member 614.

Referring now to FIG. 11D, once guidewire 616 is in a desired position and probe 602 is removed, one end of guidewire 616 may be coupled with a tissue modification device 800 at or near its distal end. In the embodiment shown, tissue modification device 800 includes a low-profile segment 808, which includes a tissue modifying portion 802 having two cutting blades 804, a guidewire connector 806 near the distal end of low-profile segment 808, a shaft 810 extending proximally from low-profile segment 808, and a proximal handle 812 coupled with shaft 810. In the embodiment shown, guidewire 616 may be pulled through the patient's back to pull tissue modification device 800 into the patient's back and to a desired position for performing a tissue modification procedure. In an alternative embodiment, tissue modification device 800 may be advanced over guidewire 616, such as over a guidewire lumen in tissue modification device 800, into the patient.

FIG. 11E shows tissue modification device 800 in position for performing a tissue modification procedure, with tissue modifying portion 802 located between target and non-target (i.e., nerve root) tissue and facing the target tissue. Additionally, a distal handle 814 has been removably coupled with guidewire 616. Handle 814 may include a lever 816 for clamping handle tightly to guidewire 616 to enable a user to apply tensioning and/or anchoring force to guidewire 616 and thus help urge tissue modifying portion 802 against target tissue. In various embodiments, any of a number of other tissue modification devices may be used, some of which have been described above.

Referring now to FIG. 12, a diagrammatic representation of one embodiment of a neural localization system 10 is shown. Neural localization system 10 may include a probe 23, having a first electrode 21 and a second electrode 22 (or optionally any other number of electrodes in alternative embodiments), multiple EMG electrodes 24, an output device 12, an optional user input device 16, and a processor 20. Processor 20 may include a central processing unit (“CPU”) 14 and a Digital to Analog converter (D/A) and Analog to Digital Converter (A/D) 18. CPU 14 may comprise any microprocessor having sufficient processing power to control the operation of D/A A/D converter 18 and output device 12. D/A A/D converter 18 may comprise such device having a sufficient operating cycle to generate signals as described herein and a sufficient sampling rate.

Generally, CPU 14 controls the operation of D/A A/D converter 18 and output device 12, in some embodiments based on data received from a user via user input device 16, and in other embodiments without input from the user. User input device 16 may include any input device or combination of devices, such as but not limited to a keyboard, mouse and/or touch sensitive screen. Output device 12 may include any output device or combination of devices controllable by CPU 14, such as but not limited to a computer monitor, printer and/or other computer controlled display device. System 10 generates electrical signals, which are transmitted to electrodes 21 and 22, and receives signals from EMG electrodes 24. Generally, CPU 14 may generate a digital representation of signals to be transmitted by electrodes 21 and 22, and D/A A/D converter 18 may convert the digital signals to analog signals before they are transmitted to electrodes 21 and 22. EMG electrodes 24 receive EMG or evoked muscle action potential (“EMAP”) signals generated by muscle electrically coupled to EMG electrodes 24 and to a depolarized nerve (motor unit). One or more nerves may be depolarized by one or more electrical signals transmitted by electrodes 21 and/or 22. D/A A/D converter 18 converts an analog signal received by EMG electrodes 24 into a digital signal that may be processed by CPU 14. CPU 14 may hold any suitable software for processing signals from EMG electrodes 24, to electrodes 21, 22 and the like. According to various embodiments, output device 12 may display any of a number of different outputs to a user, such as but not limited to information describing the signals transmitted to electrodes 21 and 22, information describing signals sensed by EMG electrodes 24, a visual and/or auditory warning when a nerve has been stimulated, and/or the like. In various alternative embodiments, system 10 may include additional components or a different combination or configuration of components, without departing from the scope of the present invention.

FIGS. 13A and 13B demonstrate, in diagrammatic form, one embodiment of a method for neural localization, similar to the methods described above. In these figures, a probe 850 is shown having an upper surface electrode 852 and a lower surface electrode 854, each of which is coupled with a wire 851 that extends to a signal source (not shown). A distal portion of probe 850 is disposed between two tissues, Tissue A and Tissue B. For example, Tissue A may comprise a combination of vertebral bone and ligamentum flavum tissue, and Tissue B may comprise a nerve root exiting a spine. It may be the case, during a tissue modification procedure in a spine (or in other areas of the body) that a surgeon or other practitioner places a probe between two tissues without knowing for sure what the two tissues are or which might be a target tissue and which might be nerve tissue the surgeon does not want to adversely affect or damage during the procedure. In one embodiment, using probe 850, current may be supplied to upper electrode 852, as in FIG. 13A. If the initial amount of current supplied does not result in measurable or observable action potentials in the nerve, as seen for example in EMG measurement, an observed or felt muscle twitch, and/or other indicia of response, it may be surmised that upper electrode 852 is not in contact with or immediately adjacent nerve tissue. In one embodiment, the amount of current delivered to upper electrode 852 may be adjusted until a threshold (or minimal) amount of current required to stimulate measurable action potentials in the nerve is determined. It has been found that on some probes 850 an electrode not immediately in contact with or adjacent a nerve may still stimulate the nerve if enough current is delivered.

Referring to FIG. 13B, current may also be delivered to lower electrode 854, which in this case happens to be in contact with Tissue B, a nerve root. The threshold amount of current required to stimulate measurable action potentials via lower electrode 854 will most likely be significantly less than the amount required to stimulate measurable action potentials via upper electrode 852. Of course, the difference between the threshold current amounts may differ depending on the thickness, width or material of the distal portion of the probe, the shape or location of electrodes 852, 852 relative to probe 850, various characteristics of the tissues themselves, and/or the like. As an example, however, a threshold amount of current required from an electrode farthest from neural tissue on a probe may be greater than about 2 milliamps, while a threshold amount of current required from an electrode closest to neural tissue on the same probe may be less than about 1 milliamp. In another example, a threshold amount of current required from an electrode farthest from neural tissue on a probe may be greater than about 1 milliamp, while a threshold amount of current required from an electrode closest to neural tissue on the same probe may be less than about 0.1 milliamp. Thus, in some embodiments, it may take at least about two times more current, and more preferably at least about ten times more current, provided to an electrode on a probe surface facing opposite neural tissue than on a probe surface directly facing neural tissue to stimulate measurable action potentials. Therefore, in one embodiment, the amounts of current required to stimulate a nerve response via two different electrodes on a probe may be compared to help determine the location of nerve tissue. In some embodiments, a ratio between the two amounts of required current may be calculated.

Referring now to FIGS. 14A and 14B, in another exemplary procedure, probe 850 may be inserted so that Tissue A (bone/ligament) and Tissue B (nerve root) are on the same side of the distal portion of probe. In this example, as demonstrated in FIG. 14A, when upper electrode 852 is activated, the nerve root (Tissue B) will be stimulated with a relatively low amount of current. This might quickly tell a surgeon that probe 850 is positioned under the nerve root. The surgeon may then further confirm the location of probe 850 relative to Tissues A and B by activating lower electrode 854, as in FIG. 14B. It would likely take significantly more current to stimulate the nerve root via lower electrode 854 than it did via upper electrode 852, thus confirming probe's 850 location under the nerve root. In some instances, where the surgeon is trying to position probe 850 above nerve root tissue, he/she may then remove and reposition probe 850 to achieve a desired positioning.

In various alternative embodiments, any of a number of alternative methods for positioning a probe and localizing neural tissue may be used. For example, some embodiments may involve using only one electrode on one surface of a probe, while others may involve using more than two electrodes. Any combination of electrodes and comparisons of current required to stimulate a measurable action potential or other indication of nerve response may be used, without departing from the scope of the present invention. As another example, the order in which current is delivered to various electrodes may be altered in different embodiments.

Furthermore, and with reference now to FIGS. 15A-15D, in various embodiments, any of a number of nerve stimulation and/or tissue distinguishing techniques and devices may be employed, either alone or in combination. The examples described above have generally been directed to the use of electrodes, such as radiofrequency (RF) electrodes. In alternative embodiments, however, it may be possible to examine tissue densities using ultrasound, piezoelectric devices, optical coherence tomography (OCT), or the like. By examining tissue density, it may be possible to distinguish tissues that a surgeon wishes to avoid, such as nerve and blood vessel, from target tissues, such as ligament and bone.

In one embodiment, for example, a probe 970 may include an upper ultrasound transducer 972 on an upper surface of its distal portion and a lower ultrasound transducer 974 on a lower surface of its distal portion. Ultrasound energy may be delivered from transducers 972, 974 and time of flight and/or amplitude of reflected signals may be measured. If probe 970 is positioned between bone/ligament (Tissue A) and neural tissue (Tissue B), for example, its position may be confirmed by applying ultrasound energy separately from upper transducer 972 and lower transducer 974. Harder tissues, like bone, will reflect ultrasound energy faster (shorter time of flight) and with higher amplitude than softer tissues, like nerve. For example, FIG. 15B diagrammatically shows exemplary signal measurements 972a, 974a from upper transducer 972 and lower transducer 974, respectively. When probe 970 is positioned as in FIG. 15A and upper transducer 972 is activated (such as in pulse mode), signal measurement 972a may show a transmitted signal T1 and a reflected signal R1. The reflected signal R1 may return quickly from the nearby, relatively hard bone/ligament tissue, and may have an amplitude almost the same as the transmitted signal T1. When lower transducer 974 is activated, it reflects off of neural tissue and thus, signal measurement 974a shows the transmitted signal T2 and then a reflected signal R2 with a longer time of flight and smaller amplitude than the received signal R1.

If probe 970 is placed under the bone/ligament and nerve root, as in FIG. 15C, it would be expected that ultrasound signals would look differently, as shown in the signal measurements 972a, 974a of FIG. 15D. When upper transducer 972 is activated, creating a first transmitted signal T1, a first reflected signal R1 with a smaller amplitude will come back first from the nearby nerve tissue, and then a second reflected signal R3 with a larger amplitude will come back from the bone/ligament tissue sometime later. When lower transducer 974 is activated, creating a second transmitted signal T2, a third reflected signal R3 will come back at some point from adjacent tissue and look different than first or second reflected signals R1 and R2. Using these or other combinations of ultrasound transducers and signals may help a surgeon or other user of probe 970 confirm that a desired probe positioning has been achieved. Various embodiments of a probe may thus include any suitable combination of ultrasound transducers and/or other devices such as electrodes, OCT devices or the like.

Referring now to FIGS. 16A-16C, one embodiment of a probe device 620 for facilitating passage of a guidewire 632 to a desired location in a patient is shown in greater detail. In the embodiment shown, probe 620 includes a shaft portion 622 having a proximal opening 623, a distal curved portion 626 having a distal opening 625, a tubular, curved guide member 624, a guide member slide 634 disposed in a channel 636, a guidewire slide 638 disposed in another channel 640, an upper surface electrode 628 coupled with distal portion 626, and a first wire 630 coupled with upper surface electrode 628 and disposed along the length of probe 620 to extend to a power source (not shown). This embodiment may further include a lower surface electrode (not visible) coupled with a second wire 631. Alternative embodiments may include only one electrode or more than two electrodes.

Distal portion 626 generally has a configuration with at least two major sides or surfaces, such as an upper surface and a lower surface. Electrode 628 (or multiple electrodes in some embodiments) may be disposed on upper and lower surfaces, as described previously, to test tissue above and below distal portion 626. In some embodiments, electrode 628 or an array of electrodes may be disposed along a length of a longitudinal axis of distal portion 626. This axial length may approximate a length of tissue to be treated by a subsequently placed device, and thus the axial length of electrode 628 may help verify that the length of tissue to be treated does not include neural tissue. Thus, electrode 628 may be described as being disposed along an “axial verification length” of distal portion 626. As explained previously, in some embodiments, guide member 624 may be housed predominantly or entirely within a guide member lumen 635 (shown in FIG. 16C) in probe 620 to facilitate delivery of probe 620 into a patient, and guide member 624 may then be advanced, using slide 634, to wholly or partially extend out of distal opening 625. Slide 634 is coupled with guide member 624 and may be used to advance and retract guide member 624 into the probe's lumen 635. Guidewire 632 may be advanced into proximal opening 623, through a guidewire lumen 633 (shown in FIG. 16C) in shaft 622, and then into and through guide member 624. In one embodiment, as shown, optional guidewire slide 638 may be included to help advance guidewire 632. Other embodiments may not include guidewire slide 638.

FIG. 16B is a front view of probe 620, and FIG. 16C is a side, cross-sectional view of probe 620, along line A-A of FIG. 16B. FIG. 16C shows guide member lumen 635 and guidewire lumen 633 of probe 620, neither of which is visible in FIGS. 16A and 16B. As seen in FIG. 16C, guidewire lumen 633 and the inner lumen of guide member 624 create one continuous lumen through which guidewire 632 may pass.

As shown in FIG. 16A, in one embodiment, electrode 628 has a long, thin configuration and extends along a length of distal curved portion 626 and around one side of distal opening 625. In various embodiments, distal portion 626 may also include one or more similar (or differently configured) electrodes on a bottom surface, side surface and/or any other surface.

With reference now to FIGS. 17A-17E, any given electrode on a probe may have any of a number of different configurations. For example, as shown in FIG. 17A, in one embodiment, an electrode 860 may stop before distal opening 625. In another embodiment, as in FIG. 17B, an electrode 870 may extend along the probe, around distal opening 625, and back up another side of the same surface of the probe. In another embodiment, as in FIG. 17C, multiple spot electrodes 880 may be used, and they may be activated all at once or separately, in various embodiments. As in FIG. 17D, in another embodiment, a circular electrode 890 may surround distal opening 625 and be connected to the shaft of the probe via a wire 892. In yet another embodiment, as in FIG. 17E, a first electrode 900 may be coupled with an upper surface of the probe, while a second electrode 902 may be coupled with a side surface. FIGS. 17A-17E are provided for exemplary purposes. Any of a number of other suitable electrode configurations and combinations may be included in alternative embodiments.

In a number of the examples described above, one or more electrodes, ultrasound transducers and/or the like are disposed on upper and/or lower surfaces of a distal portion of a shaft of a probe, and a curved guide member may be extended out of a distal opening on the probe shaft. In various alternative embodiments, and with reference now to FIGS. 18A and 18B, one or more electrodes may be located on a curved guide member extending from a probe shaft (or needle) instead of or in addition to locating one or more electrodes on the probe shaft. In yet another alternative embodiment, one or more electrodes may alternatively or additionally be placed on a guidewire, such as a flat guidewire.

In one embodiment, shown in FIG. 18A, a distal portion of a probe shaft 980 includes a distal opening 982, and a flat guide member 984 extends out of distal opening 982. Flat guide member 984 may include an upper surface electrode 986, a lower surface electrode (not visible), and a distal opening 987, through which a guidewire may pass. In this embodiment, guide member 984 has a flat (or flattened oval) cross-sectional shape so that it has upper and lower surfaces. This allows a user to separately activate upper electrode 986 and the lower surface electrode to help confirm a location of guide member 984 relative to neural tissue and/or other tissue in a body. Guide member 984 may have other shapes in alternative embodiments, but will typically have a shape having at least two sides, to facilitate determination of the orientation of guide member 984 relative to tissue.

In an alternative embodiment, shown in FIG. 18B, a needle 990, such as an epidural needle, may be used to access an epidural space of the spine. Needle 990 may include a distal opening 992, and a guide member 994 may extend from opening 992. Guide member 994 may include an upper surface electrode 996, a lower surface electrode (not visible) and a distal opening 997. In some embodiments, guide member 994 may expand or unfold upon exiting distal opening 992 of needle 990 to assume a flat configuration. Again, guide member 994 may have any of a number of configurations, cross-sectional shapes and the like, but will often have a shape with at least two sides, for helping confirm an orientation of guide member 994 relative to tissue.

In further alternative embodiments, and with reference now to FIGS. 19A-19C, it may sometimes be advantageous to have a steerable or shape changing probe 950. For example, probe 950 (only a distal portion of which is shown) may include an articulating distal portion 952. Distal portion 952 may articulate, for example, from a straighter configuration, as in FIG. 19A, to a more bent configuration, as in FIG. 19B, and then to a curved/bent configuration, as in FIG. 19C. Any of a number of different mechanisms, actuators and the like may be used to articulate such a distal portion 952 in various embodiments. For example, in the embodiment shown, multiple slits 954 may be disposed along one side of distal portion 952, and one or more pull wires (not visible) may be coupled with distal portion 952 and extend to a more proximal portion of probe 950 to enable a user to pull the wires to bend/curve distal portion 952. In another embodiment, push rods might be used to straighten distal portion 952. A number of different technologies are known for articulating various tools, and any such suitable technology may be applied in various embodiment of probe 950. In some embodiments where such an articulating distal end 952 is included, probe 950 may not include a curved guide member, and instead, a guidewire 956 may be advanced directly out of a distal opening on probe 950, as shown in FIG. 19C. Articulating distal end 952 may facilitate advancement of probe 950 into narrow passages and/or use of a percutaneous or less invasive approach to a given target tissue.

FIGS. 20A and 20B illustrate another alternative embodiment of a probe device 640, in front and side cross-sectional views, respectively. In this embodiment, probe 640 may include a shaft portion 642, two curved ends 664, 644 extending from opposite ends of shaft 642, two tubular channels 666, 667, a guide member 646, electrodes 650, 652 coupled with one end 644, wires 656, 658 coupled with electrodes 650, 652, and a common extension 660 of wires 656, 658, which splits to two separate power connectors 662. In this embodiment, it may be possible to use one end 644 for accessing one part of a spine, for example, and to use the opposite end 664 for accessing another part of the spine or the same part from a different approach or angle. For example, it may sometimes be desirable to pass probe 640 through an opening between two vertebrae, into the epidural space, and between an ipsilateral interverebral foramen. During the same procedure, or in an alternative procedure, it may be desirable to pass probe 640 into the contralateral intervertebral foramen. Thus, ends 644, 664 may have different shapes, lengths, radii of curvature or the like, to facilitate access to different spaces and/or different approaches to the same space. In some embodiments, both ends 644, 664 may have guide members 646 and/or electrodes 650, 652, while in other embodiments, only one end 644 may include these features. In some embodiments, it may be possible to remove guide member from one channel 667 and advance it into the other channel 666. Although no slide device is shown in this embodiment, a slide may optionally be added, or guide member 646 may be advanced and/or retracted manually.

Referring now to FIG. 20C, guide member 646 from the embodiment in FIGS. 20A and 20B may have a cylindrical shape with a blunt distal end 647. In an alternative embodiment, as in FIGS. 21A and 21B, a guide member 960 may have a tapered distal end 962 with a longitudinal slit 964 that opens into a guidewire lumen 961 (dotted lines). When a guidewire 966 is advanced through the guidewire lumen, as in FIG. 21B, slit 964 opens to allow guidewire 966 to exit distal end 962. Slit 964 allows distal end 962 to remain closed while being advanced through tissue, and the tapered distal end 962 facilitates atraumatice passage of the guide member through tissue. In an alternative embodiment, distal end 962 may include a circular opening at its far distal tip, rather than slit 962.

With reference now to FIGS. 22A-22C, three additional embodiments of various probe devices 670, 680, 690 are shown. As illustrated in FIG. 22A, in one embodiment, a probe 670 may include opposite curved ends 672, 674 with similar radii of curvature. In another embodiment, as in FIG. 22B, a probe 680 may include opposite ends 682, 684 with different radii of curvature. This may be advantageous, for example, in facilitating access to two different areas in a spine or to the same area from two different approaches, as described above. In some embodiments, one or both extreme distal ends of probe 680 may include a toe 683, 685 (or lip), comprising a tip with a steeper radius of curvature than an immediately proximal portion of probe 680. Such a toe 683, 685 may facilitate, for example, acquiring tactile feedback when applied against a bony surface.

FIG. 22C shows another embodiment of a probe 690, in this case shown with electrodes 698, 700 coupled with wires 702, 704 extending to a common cord 706 that splits to two power connectors 708. In this embodiment, probe's 690 two opposite curved ends 692, 696 have slightly different shapes, with one end 692 having a lip 694. Such a lip 694 may help facilitate tactile sensation during placement of probe 690. In various embodiments, a system or set of multiple probes may be provided, each probe having different characteristics, shapes, sizes or the like, to provide a surgeon or other practitioner with alternative probes during a procedure.

Referring to FIGS. 23A and 23B, in some embodiments it may be advantageous to use a probe device 910 in a spine where a decompression implant 922 has been placed. For example, decompression implant 922 shown in FIGS. 23A and 23B is the X STOP® Interspinous Process Decompression (IPD®), offered by St. Francis Medical Technologies, Inc.® (Alameda, Calif.). In one embodiment, probe 910, which is shown in top view in FIG. 23A and partial side view in FIG. 23B, may include a shaft 912 with a guidewire channel 914 and a curved side surface 916, and a distal curved portion 918 with a distal opening 920. Curved side surface 916 may be shaped to slide along a complementary surface 917 of decompression implant 922 as probe 910 is advanced into the patient, which may facilitate guiding probe 910 to a desired position, such as to position distal portion 918 in an intervertebral foramen, as in FIG. 23B. In various alternative embodiments, probe 910 may have any of a number of configurations and sizes to conform to or fit within any of a number of spinal decompression implants.

In another embodiment, and with reference now to FIGS. 24 and 25, in some instances a probe device 936 may be used with one or more tubular spinal access conduit devices 930. Examples of such access systems include the METRx™ System, offered by Medtronic Sofamor Danek (Minneapolis, Minn.), the Harmony™ PLIF Instrument System, offered by Spinal Concepts, Inc. (Austin, Tex.) and the Atavi® Atraumatic Spin Surgery System, offered by Endius, Inc. (Plainville, Mass.). In one embodiment, as shown in FIG. 24, probe 936 may include a surface 938 or overall configuration to facilitate its advancement along a complementary surface 932 on a guide member 934 in access conduit 930. In the same or an alternative embodiment, probe 936 may be shaped to pass through a channel 942 in a conduit device 940, as in FIG. 25. In some embodiments, probe 936 may be compatible with multiple different conduit devices 930, 940. In other embodiments, multiple probes may be provided in a set, to provide compatibility with multiple different conduit devices 930, 940. In various embodiments of the invention, a system may be provided, including one or more probe devices, one or more decompression implants and/or one or more access conduits.

Referring now to FIGS. 26A-26E, in the embodiments described above, the various tissue modification devices 102, 202 include at least one non-tissue-modifying (or “protective”) portion, side or surface. The non-tissue-modifying portion is located on tissue modification device 102, 202 so as to be positioned adjacent non-target tissue when tissue modifying members 110, 210 are facing the target tissue. The non-tissue-modification surface of the device is configured so as to not modify or damage tissue, and thus the non-target tissue is protected from unwanted modification or damage during a tissue modification procedure.

Optionally, in some embodiments, tissue modification devices or systems may further include one or more tissue shields or barriers for further protecting non-target tissues. Such shields may be slidably coupled with, fixedly coupled with, or separate from the tissue modification devices with which they are used. In various embodiments, a shield may be delivered between target and non-target tissues before delivering the tissue modification device, may be delivered along with the tissue modification device, or may be delivered after delivery of the tissue modification device but before the device is activated. Generally, such a shield would be interposed between the non-target tissue and the tissue modification device.

FIG. 26A shows a distal portion of an introducer device 514 through which a shield may be introduced. FIGS. 26B and 26C show one embodiment of a shield device 500 partially deployed and in cross-section, respectively. Typically, shield 500 will have a first, small-profile configuration for delivery to an area near non-target tissue and a second, expanded configuration for protecting the non target tissue. Shield itself may be configured as one piece of super-elastic or shape-memory material, as a scaffold with material draped between the scaffolding, as a series of expandable wires or tubes, as a semicircular stent-like device, as one or more expandable balloons or bladders, as a fan or spring-loaded device, or as any of a number of different devices configured to expand upon release from a delivery device to protect tissue. As shown in FIGS. 26B and 26C, shield 500 may comprise a sheet of material disposed with a first end 502a abutting a second end 502b within introducer device 514 and unfurling upon delivery. In an alternative embodiment, as shown in FIGS. 26D and 26E, opposite ends 522a and 522b of a shield device 520 may overlap in introducer device 514. Generally, shield 500, 520 may be introduced via introducer device 514 in one embodiment or, alternatively, may be introduced via any of the various means for introducing the tissue modification device, such as those described in conjunction with FIGS. 7A-7S, 8A-8F, 9A-9B, 10A-10F, and 11A-11E. In some embodiments, shield 500, 520 may be fixedly coupled with or an extension of a tissue modification device. Shield 500, 520 may also include one or more lumens, rails, passages or the like for passing a guidewire or other guide member, for introducing, removing or exchanging any of a variety of tissue modification, drug delivery, or diagnostic devices, for passing a visualization device, for providing irrigation fluid at the tissue modification site, and or the like. In some embodiments, shield 500, 520 is advanced over multiple guidewires and the guidewires remain in place during a tissue modification procedure to enhance the stability and/or maintain positioning of shield 500, 520.

Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. For example, in many of the embodiments described above, one or more abrasive tissue modifying members may be substituted for one or more bladed tissue modifying members or vice versa. These an many other modifications may be made to many of the described embodiments. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.

Claims

1. A method for locating neural tissue in a patient's intervertebral foramen, so that the neural tissue can be avoided when decompressing the intervertebral foramen, the method comprising: advancing a probe along a path within an intervertebral foramen, the probe having a first surface oriented anteriorly and towards neural tissue within the intervertebral foramen and a second surface oriented posteriorly and away from the neural tissue;delivering a first electrical current to a first electrode along the first surface of the probe;delivering a second electrical current to a second electrode along the second surface of the probe;verifying that the neural tissue is anterior to the probe in the intervertebral foramen by monitoring neural response to the first and second electrical currents;determining a first threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the first electrode;determining a second threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the second electrode;comparing the first and second threshold amounts of current to determine which of the first and second surfaces is closest to the neural tissue;calculating a ratio of the threshold amount of current applied to the electrode farthest from the neural tissue compared to the threshold amount of current applied to the electrode closest to the neural tissue; andremoving tissue from the intervertebral foramen posterior to the path of the probe with a tissue modification device, to reduce impingement of the neural tissue when the ratio is greater than or equal to 2.
2. A method as in claim 1, wherein the probe comprises an elongate flattened body having an axis and a distal end, the first and second surfaces comprising opposed major surfaces of the elongate body.
3. A method as in claim 1, wherein advancing the probe comprises advancing a distal portion of the probe along an interface between a bone or ligament surface and a soft tissue surface.
4. A method as in claim 1, further comprising advancing a curved, shape-memory guide member having at least one lumen out of a distal opening on the probe device.
5. A method as in claim 1, further wherein the step of removing tissue from the intervertebral foramina comprises removing the tissue when the threshold amount of current applied to the electrode closest to the neural tissue is less than about 1 milliamp, and wherein the amount of threshold current applied to the electrode farthest from the neural tissue is greater than about 2 milliamps.
6. A method as in claim 1, wherein monitoring the neural response to the first and second currents comprises monitoring at least one of somatosensory evoked potentials (SSEP), motor evoked potentials (MEP), electromyography (EMG), visible muscle twitch and tactile muscle twitch.
7. The method of claim 1, further comprising shielding the neural tissue from the tissue modification device.
8. The method of claim 1, further wherein removing tissue from the intervertebral foramen comprises abrasively removing tissue.
9. A method for locating neural tissue in a patient's intervertebral foramen, so that the neural tissue can be avoided when decompressing the intervertebral foramen, the method comprising: advancing a probe along a path within an intervertebral foramen, the probe having a first surface oriented anteriorly and toward neural tissue within the intervertebral foramen and a second surface oriented posteriorly and away from the neural tissue;delivering a first electrical current to a first electrode along the first surface of the probe;delivering a second electrical current to a second electrode along the second surface of the probe;maintaining orientation of the probe as it is advanced so that the first surface of the advanced probe remains oriented anteriorly and towards the neural tissue and the second surface remains oriented posteriorly and away from the neural tissue by monitoring neural response to the first and second electrical currents;determining a first threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the first electrode;determining a second threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the second electrode;comparing the first and second threshold amounts of current to determine which of the first and second surfaces is closest to the neural tissue;calculating a ratio of the threshold amount of current applied to the electrode farthest from the neural tissue compared to the threshold amount of current applied to the electrode closest to the neural tissue; andcutting tissue from the intervertebral foramen posterior to the path of the probe with a tissue modification device to reduce impingement of the neural tissue in the intervertebral foramen when the ratio is greater than or equal to 2.
10. The method of claim 9, wherein the probe comprises an elongate flattened body having an axis and a distal end, the first and second surfaces comprising opposed major surfaces of the elongate body.
11. A method as in claim 9, wherein the probe is advanced along a tissue interface between two adjacent tissue planes, and advancing the probe causes the probe's distal end to dissect the neural tissue from the other tissue along the tissue interface, the other tissue comprising an impinging tissue and being harder than the neural tissue.
12. A method for locating neural tissue in a patient's intervertebral foramen, so that the neural tissue can be avoided when decompressing the intervertebral foramen, the method comprising: advancing a probe along a path within an intervertebral foramen, the probe having a first surface oriented anteriorly and toward neural tissue within the intervertebral foramen and a second surface oriented posteriorly and away from the neural tissue;delivering a first electrical current to a first electrode along the first surface of the probe;delivering a second electrical current to a second electrode along the second surface of the probe;maintaining orientation of the probe as it advances, so that the first surface of the advanced probe remains oriented anteriorly and towards the neural tissue and the second surface remains oriented posteriorly and away from the neural tissue, by monitoring neural response to the first and second electrical currents;determining a first threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the first electrode;determining a second threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the second electrode;comparing the first and second threshold amounts of current to determine which of the first and second surfaces is closest to the neural tissue;calculating a ratio of the threshold amount of current applied to the electrode farthest from the neural tissue compared to the threshold amount of current applied to the electrode closest to the neural tissue; andabrasively removing tissue from the intervertebral foramen posterior to the path of the probe with a tissue modification device to reduce impingement of the neural tissue when the ratio is greater than or equal to 2.
13. The method of claim 12, further comprising shielding the neural tissue.
14. A method for locating neural tissue in a patient's intervertebral foramen, so that the neural tissue can be avoided when decompressing the intervertebral foramen, the method comprising: advancing a probe along a path within an intervertebral foramen, the probe having a first surface oriented anteriorly and towards neural tissue within the intervertebral foramen and a second surface oriented posteriorly and away from the neural tissue;delivering a first electrical current to a first electrode along the first surface of the probe;delivering a second electrical current to a second electrode along the second surface of the probe;verifying that the neural tissue is anterior to the probe in the intervertebral foramen by monitoring neural response to the first and second electrical currents;determining a first threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the first electrode;determining a second threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the second electrode;comparing the first and second threshold amounts of current, to determine which of the first and second surfaces is closest to the neural tissue;calculating a ratio of the threshold amount of current applied to the electrode farthest from the neural tissue compared to the threshold amount of current applied to the electrode closest to the neural tissue, andremoving tissue from the intervertebral foramen posterior to the path of the probe with a tissue modification device to reduce impingement of the neural tissue when the ratio is greater than or equal to about 2.
15. A method for locating neural tissue in a patient's intervertebral foramen, so that the neural tissue can be avoided when decompressing the intervertebral foramen, the method comprising: advancing a probe along a path within an intervertebral foramen, the probe having a first surface oriented towards neural tissue within the intervertebral foramen and a second surface oriented away from the neural tissue;delivering a first electrical current to a first electrode along the first surface of the probe;delivering a second electrical current to a second electrode along the second surface of the probe;determining a first threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the first electrode;determining a second threshold amount of electrical current required to stimulate measurable action potentials in the neural tissue via the second electrode;comparing the first and second threshold amounts of current, to determine which of the first and second surfaces is closest to the neural tissue;calculating a ratio of the threshold amount of current applied to the electrode farthest from the neural tissue compared to the threshold amount of current applied to the electrode closest to the neural tissue, andremoving tissue from the intervertebral foramen adjacent to the path of the second surface of the probe when the ratio is greater than or equal to about 2.
16. The method of claim 1, wherein the step of advancing the probe comprises advancing the probe over a wire.
17. The method of claim 1, wherein the step of advancing the probe comprises pulling the probe within the intervertebral foramen with a wire.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of U.S. patent application Ser. No. 11/251,205, entitled “Devices and Methods for Tissue Access,” filed on Oct. 15, 2005, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/681,864, entitled “Method and Apparatus for Selective Surgical Removal of Tissue,” filed on May 16, 2005; and is also a continuation-in-part of U.S. patent application Ser. No. 11/375,265, entitled “Methods and Apparatus for Tissue Modification,” filed on Mar. 13, 2006. The entire disclosures of all of the above applications are hereby incorporated by reference.

US Referenced Citations (431)

Number	Name	Date	Kind
8250	Stohlmann	Nov 1876	A
289104	Woodbury	Nov 1883	A
863389	Harkin	Aug 1907	A
1039487	Casebolt	Sep 1912	A
1201467	Hoglund	Oct 1916	A
1374638	De Cew et al.	Apr 1921	A
1543195	Thygesen	Jun 1925	A
1690812	Bertels	Nov 1928	A
1938200	Wells	Dec 1933	A
2243757	Kohls et al.	May 1941	A
2269749	Wilkie	Jan 1942	A
2372553	Coddington	Mar 1945	A
2437697	Kalom	Mar 1948	A
2516882	Kalom	Aug 1950	A
2704064	Fizzell et al.	Mar 1955	A
2820281	Amsen	Jan 1958	A
2843128	Storz	Jul 1958	A
2982005	Booth	May 1961	A
RE25582	Davies	May 1964	E
3389447	Theobald et al.	Jun 1968	A
3495590	Zeiller	Feb 1970	A
3528152	Funakubo et al.	Sep 1970	A
3624484	Colyer	Nov 1971	A
3640280	Slanker et al.	Feb 1972	A
3664329	Naylor	May 1972	A
3682162	Colyer	Aug 1972	A
3699729	Garvey et al.	Oct 1972	A
3752166	Lyon et al.	Aug 1973	A
3774355	Dawson et al.	Nov 1973	A
3830226	Staub et al.	Aug 1974	A
3835859	Roberts et al.	Sep 1974	A
3956858	Catlin et al.	May 1976	A
3957036	Normann	May 1976	A
3978862	Morrison	Sep 1976	A
4099519	Warren	Jul 1978	A
4108182	Hartman et al.	Aug 1978	A
4160320	Wikoff	Jul 1979	A
4203444	Bonnell et al.	May 1980	A
4207897	Lloyd et al.	Jun 1980	A
4259276	Rawlings	Mar 1981	A
4405061	Bergandy	Sep 1983	A
D273806	Bolesky et al.	May 1984	S
4502184	Karubian	Mar 1985	A
4515168	Chester et al.	May 1985	A
4545374	Jacobson	Oct 1985	A
4573448	Kambin	Mar 1986	A
4590949	Pohndorf	May 1986	A
4616660	Johns	Oct 1986	A
4621636	Fogarty	Nov 1986	A
4625725	Davison et al.	Dec 1986	A
4660571	Hess et al.	Apr 1987	A
4678459	Onik et al.	Jul 1987	A
4690642	Kyotani	Sep 1987	A
4700702	Nilsson	Oct 1987	A
4709699	Michael et al.	Dec 1987	A
4808157	Coombs	Feb 1989	A
4856193	Grachan	Aug 1989	A
4867155	Isaacson	Sep 1989	A
4872452	Alexson	Oct 1989	A
4873978	Ginsburg	Oct 1989	A
4883460	Zanetti	Nov 1989	A
RE33258	Onik et al.	Jul 1990	E
4962766	Herzon	Oct 1990	A
4990148	Worrick, III et al.	Feb 1991	A
4994036	Biscoping et al.	Feb 1991	A
4994072	Bhate et al.	Feb 1991	A
4995200	Eberhart	Feb 1991	A
5019082	Frey et al.	May 1991	A
5026379	Yoon	Jun 1991	A
5026386	Michelson	Jun 1991	A
5089003	Fallin et al.	Feb 1992	A
5100424	Jang et al.	Mar 1992	A
5108403	Stern	Apr 1992	A
5125928	Parins et al.	Jun 1992	A
5147364	Comparetto	Sep 1992	A
5163939	Winston	Nov 1992	A
5176649	Wakabayashi	Jan 1993	A
5178145	Rea	Jan 1993	A
5201704	Ray	Apr 1993	A
5215105	Kizelshteyn et al.	Jun 1993	A
5219358	Bendel et al.	Jun 1993	A
5250035	Smith et al.	Oct 1993	A
5255691	Otten	Oct 1993	A
5281218	Imran	Jan 1994	A
5284153	Raymond et al.	Feb 1994	A
5284154	Raymond et al.	Feb 1994	A
5300077	Howell	Apr 1994	A
5341807	Nardella	Aug 1994	A
5353789	Schlobohm	Oct 1994	A
5353802	Ollmar	Oct 1994	A
5383879	Phillips	Jan 1995	A
5387218	Meswania	Feb 1995	A
5396880	Kagan et al.	Mar 1995	A
5437661	Rieser	Aug 1995	A
5439464	Shapiro	Aug 1995	A
5441510	Simpson et al.	Aug 1995	A
5454815	Geisser et al.	Oct 1995	A
5496325	McLees	Mar 1996	A
5512037	Russell et al.	Apr 1996	A
5531749	Michelson	Jul 1996	A
5554110	Edwards et al.	Sep 1996	A
5555892	Tipton	Sep 1996	A
5560372	Cory	Oct 1996	A
5562695	Obenchain	Oct 1996	A
5582618	Chin et al.	Dec 1996	A
5598848	Swanson et al.	Feb 1997	A
5620447	Smith et al.	Apr 1997	A
5630426	Eggers et al.	May 1997	A
5643304	Schechter et al.	Jul 1997	A
5680860	Imran	Oct 1997	A
5681324	Kammerer et al.	Oct 1997	A
5697889	Slotman et al.	Dec 1997	A
5709697	Ratcliff et al.	Jan 1998	A
5725530	Popken	Mar 1998	A
5735792	Vanden Hoek et al.	Apr 1998	A
5755732	Green et al.	May 1998	A
5759159	Masreliez	Jun 1998	A
5762629	Kambin	Jun 1998	A
5766168	Mantell	Jun 1998	A
5769865	Kermode et al.	Jun 1998	A
5775331	Raymond et al.	Jul 1998	A
5779642	Nightengale	Jul 1998	A
5795308	Russin	Aug 1998	A
5800350	Coppleson et al.	Sep 1998	A
5803904	Mehdizadeh	Sep 1998	A
5807263	Chance	Sep 1998	A
5810744	Chu et al.	Sep 1998	A
5824040	Cox et al.	Oct 1998	A
5830151	Hadzic et al.	Nov 1998	A
5833692	Cesarini et al.	Nov 1998	A
5843110	Dross et al.	Dec 1998	A
5846196	Siekmeyer et al.	Dec 1998	A
5846244	Cripe	Dec 1998	A
5851191	Gozani	Dec 1998	A
5851209	Kummer et al.	Dec 1998	A
5851214	Larsen et al.	Dec 1998	A
5853373	Griffith et al.	Dec 1998	A
5868767	Farley et al.	Feb 1999	A
5879353	Terry	Mar 1999	A
5885219	Nightengale	Mar 1999	A
5897583	Meyer et al.	Apr 1999	A
5899909	Claren et al.	May 1999	A
5919190	VanDusseldorp	Jul 1999	A
5928158	Aristides	Jul 1999	A
5928159	Eggers et al.	Jul 1999	A
5941822	Skladnev et al.	Aug 1999	A
5961522	Mehdizadeh	Oct 1999	A
5976110	Greengrass et al.	Nov 1999	A
5976146	Ogawa et al.	Nov 1999	A
6002964	Feler et al.	Dec 1999	A
6004326	Castro et al.	Dec 1999	A
6010493	Snoke	Jan 2000	A
6022362	Lee et al.	Feb 2000	A
6030383	Benderev	Feb 2000	A
6030401	Marino	Feb 2000	A
6048345	Berke et al.	Apr 2000	A
6068642	Johnson et al.	May 2000	A
6099514	Sharkey et al.	Aug 2000	A
6102930	Simmons, Jr.	Aug 2000	A
6106558	Picha	Aug 2000	A
6113534	Koros et al.	Sep 2000	A
D432384	Simons	Oct 2000	S
6136014	Sirimanne et al.	Oct 2000	A
6142993	Whayne et al.	Nov 2000	A
6146380	Racz et al.	Nov 2000	A
6169916	West	Jan 2001	B1
6205360	Carter et al.	Mar 2001	B1
6214001	Casscells et al.	Apr 2001	B1
6256540	Panescu et al.	Jul 2001	B1
6259945	Epstein et al.	Jul 2001	B1
6261582	Needham et al.	Jul 2001	B1
6266551	Osadchy et al.	Jul 2001	B1
6272367	Chance	Aug 2001	B1
6277094	Schendel	Aug 2001	B1
6280447	Marino et al.	Aug 2001	B1
6292702	King et al.	Sep 2001	B1
6298256	Meyer	Oct 2001	B1
6312392	Herzon	Nov 2001	B1
6324418	Crowley et al.	Nov 2001	B1
6343226	Sunde et al.	Jan 2002	B1
6358254	Anderson	Mar 2002	B1
6360750	Gerber et al.	Mar 2002	B1
6364886	Sklar	Apr 2002	B1
6368324	Dinger et al.	Apr 2002	B1
6370411	Osadchy et al.	Apr 2002	B1
6370435	Panescu et al.	Apr 2002	B2
6383509	Donovan et al.	May 2002	B1
6390906	Subramanian	May 2002	B1
6391028	Fanton et al.	May 2002	B1
6423071	Lawson	Jul 2002	B1
6425859	Foley et al.	Jul 2002	B1
6425887	McGuckin et al.	Jul 2002	B1
6436101	Hamada	Aug 2002	B1
6442848	Dean	Sep 2002	B1
6451335	Goldenheim et al.	Sep 2002	B1
6454767	Alleyne	Sep 2002	B2
6464682	Snoke	Oct 2002	B1
6466817	Kaula et al.	Oct 2002	B1
6470209	Snoke	Oct 2002	B2
6478805	Marino et al.	Nov 2002	B1
6487439	Skladnev et al.	Nov 2002	B1
6488636	Bryan et al.	Dec 2002	B2
6500128	Marino	Dec 2002	B2
6500189	Lang et al.	Dec 2002	B1
6512958	Swoyee et al.	Jan 2003	B1
6516223	Hofmann	Feb 2003	B2
6520907	Foley et al.	Feb 2003	B1
6527786	Davis et al.	Mar 2003	B1
6533749	Mitusina et al.	Mar 2003	B1
6535759	Epstein et al.	Mar 2003	B1
6540761	Houser	Apr 2003	B2
6546270	Goldin et al.	Apr 2003	B1
6558353	Zohmann	May 2003	B2
6562033	Shah et al.	May 2003	B2
6564078	Marino et al.	May 2003	B1
6564079	Cory et al.	May 2003	B1
6564088	Soller et al.	May 2003	B1
6569160	Goldin et al.	May 2003	B1
6575979	Cragg	Jun 2003	B1
6579291	Keith et al.	Jun 2003	B1
6592559	Pakter et al.	Jul 2003	B1
6597955	Panescu et al.	Jul 2003	B2
6606523	Jenkins	Aug 2003	B1
6609018	Cory et al.	Aug 2003	B2
6610066	Dinger et al.	Aug 2003	B2
6626916	Yeung et al.	Sep 2003	B1
6638233	Corvi et al.	Oct 2003	B2
RE38335	Aust et al.	Nov 2003	E
6648883	Francischelli et al.	Nov 2003	B2
6666874	Heitzmann et al.	Dec 2003	B2
6673063	Brett	Jan 2004	B2
6673068	Berube	Jan 2004	B1
6678552	Pearlman	Jan 2004	B2
6682535	Hoogland	Jan 2004	B2
6682536	Vardi et al.	Jan 2004	B2
6699246	Zucherman et al.	Mar 2004	B2
6723049	Skladnev et al.	Apr 2004	B2
6726531	Harrel	Apr 2004	B1
6726685	To et al.	Apr 2004	B2
6733496	Sharkey et al.	May 2004	B2
6746451	Middleton et al.	Jun 2004	B2
6752814	Gellman et al.	Jun 2004	B2
6760616	Hoey et al.	Jul 2004	B2
6772012	Ricart et al.	Aug 2004	B2
6776765	Soukup et al.	Aug 2004	B2
6788966	Kenan et al.	Sep 2004	B2
6790210	Cragg et al.	Sep 2004	B1
6805695	Keith et al.	Oct 2004	B2
6805697	Helm et al.	Oct 2004	B1
6807444	Tu et al.	Oct 2004	B2
6830561	Jansen et al.	Dec 2004	B2
6830570	Frey et al.	Dec 2004	B1
6832111	Tu et al.	Dec 2004	B2
6845264	Skladnev et al.	Jan 2005	B1
6847849	Mamo et al.	Jan 2005	B2
6851430	Tsou	Feb 2005	B2
6872204	Houser	Mar 2005	B2
6875221	Cull	Apr 2005	B2
6882879	Rock	Apr 2005	B2
6899716	Cragg	May 2005	B2
6907884	Pellegrino et al.	Jun 2005	B2
6911003	Anderson et al.	Jun 2005	B2
6916328	Brett	Jul 2005	B2
6923813	Phillips et al.	Aug 2005	B2
6929647	Cohen	Aug 2005	B2
6962587	Johnson et al.	Nov 2005	B2
6972199	Lebowitz et al.	Dec 2005	B2
6976986	Berube	Dec 2005	B2
6991643	Saadat	Jan 2006	B2
6997934	Snow et al.	Feb 2006	B2
6999820	Jordan	Feb 2006	B2
7001333	Hamel et al.	Feb 2006	B2
7008431	Simonson	Mar 2006	B2
7010352	Hogan	Mar 2006	B2
7011663	Michelson	Mar 2006	B2
7050848	Hoey et al.	May 2006	B2
7063682	Whayne et al.	Jun 2006	B1
7070596	Woloszko et al.	Jul 2006	B1
7079883	Marino et al.	Jul 2006	B2
7081122	Reiley et al.	Jul 2006	B1
7087058	Cragg	Aug 2006	B2
7107104	Keravel et al.	Sep 2006	B2
7118576	Gitis et al.	Oct 2006	B2
7141019	Pearlman	Nov 2006	B2
7166073	Ritland	Jan 2007	B2
7166081	McKinley	Jan 2007	B2
7166107	Anderson	Jan 2007	B2
7169107	Jersey-Willuhn et al.	Jan 2007	B2
7189240	Dekel	Mar 2007	B1
7198598	Smith et al.	Apr 2007	B2
7198626	Lee et al.	Apr 2007	B2
7211082	Hall et al.	May 2007	B2
7214186	Ritland	May 2007	B2
7223278	Davison et al.	May 2007	B2
7239911	Scholz	Jul 2007	B2
7282061	Sharkey et al.	Oct 2007	B2
7337005	Kim et al.	Feb 2008	B2
7337006	Kim et al.	Feb 2008	B2
20010014806	Ellman et al.	Aug 2001	A1
20010049527	Cragg	Dec 2001	A1
20010053885	Gielen et al.	Dec 2001	A1
20020016555	Ritchart et al.	Feb 2002	A1
20020019637	Frey et al.	Feb 2002	A1
20020022788	Corvi et al.	Feb 2002	A1
20020029060	Hogendijk	Mar 2002	A1
20020106681	Wexler et al.	Aug 2002	A1
20020138091	Pflueger	Sep 2002	A1
20020183647	Gozani et al.	Dec 2002	A1
20030023190	Cox	Jan 2003	A1
20030045808	Kaula et al.	Mar 2003	A1
20030105503	Marino	Jun 2003	A1
20030109871	Johnson et al.	Jun 2003	A1
20030113906	Sangha et al.	Jun 2003	A1
20030130738	Hovda et al.	Jul 2003	A1
20030167021	Shimm	Sep 2003	A1
20030187368	Sata et al.	Oct 2003	A1
20030212400	Bloemer et al.	Nov 2003	A1
20030225412	Shiraishi	Dec 2003	A1
20030225415	Richard	Dec 2003	A1
20040006379	Brett	Jan 2004	A1
20040006391	Reiley	Jan 2004	A1
20040030330	Brassell et al.	Feb 2004	A1
20040049179	Francischelli et al.	Mar 2004	A1
20040054368	Truckai et al.	Mar 2004	A1
20040059247	Urmey	Mar 2004	A1
20040064058	McKay	Apr 2004	A1
20040067000	Bates et al.	Apr 2004	A1
20040097927	Yeung et al.	May 2004	A1
20040102721	McKinley	May 2004	A1
20040106940	Shaolian et al.	Jun 2004	A1
20040111084	Brett	Jun 2004	A1
20040116977	Finch et al.	Jun 2004	A1
20040122433	Loubens et al.	Jun 2004	A1
20040122459	Harp	Jun 2004	A1
20040122482	Tung et al.	Jun 2004	A1
20040127893	Hovda	Jul 2004	A1
20040127963	Uchida et al.	Jul 2004	A1
20040133208	Weikel et al.	Jul 2004	A1
20040143165	Alleyne	Jul 2004	A1
20040162609	Hossainy et al.	Aug 2004	A1
20040167553	Simpson et al.	Aug 2004	A1
20040181150	Evans et al.	Sep 2004	A1
20040199084	Kelleher et al.	Oct 2004	A1
20040199166	Schmieding et al.	Oct 2004	A1
20040260358	Vaughan et al.	Dec 2004	A1
20050027199	Clarke	Feb 2005	A1
20050049592	Keith et al.	Mar 2005	A1
20050060006	Pflueger et al.	Mar 2005	A1
20050075578	Gharib et al.	Apr 2005	A1
20050149034	Assell et al.	Jul 2005	A1
20050149035	Pimenta et al.	Jul 2005	A1
20050149154	Cohen et al.	Jul 2005	A1
20050171587	Daglow et al.	Aug 2005	A1
20050182454	Gharib et al.	Aug 2005	A1
20050197661	Carrison et al.	Sep 2005	A1
20050203599	Garabedian et al.	Sep 2005	A1
20050209610	Carrison	Sep 2005	A1
20050209622	Carrison	Sep 2005	A1
20050234425	Miller et al.	Oct 2005	A1
20050261692	Carrison et al.	Nov 2005	A1
20050283148	Janssen et al.	Dec 2005	A1
20060004369	Patel et al.	Jan 2006	A1
20060015035	Rock	Jan 2006	A1
20060025703	Miles et al.	Feb 2006	A1
20060025797	Lock et al.	Feb 2006	A1
20060036211	Solsberg et al.	Feb 2006	A1
20060036271	Schomer et al.	Feb 2006	A1
20060036272	Solsberg et al.	Feb 2006	A1
20060058732	Harp	Mar 2006	A1
20060064101	Arramon	Mar 2006	A1
20060079919	Harp	Apr 2006	A1
20060085048	Cory et al.	Apr 2006	A1
20060085049	Cory et al.	Apr 2006	A1
20060089609	Bleich et al.	Apr 2006	A1
20060089633	Bleich et al.	Apr 2006	A1
20060089640	Bleich et al.	Apr 2006	A1
20060089650	Nolde	Apr 2006	A1
20060089688	Panescu	Apr 2006	A1
20060094976	Bleich	May 2006	A1
20060095026	Ricart et al.	May 2006	A1
20060095028	Bleich	May 2006	A1
20060095059	Bleich et al.	May 2006	A1
20060100651	Bleich	May 2006	A1
20060122458	Bleich	Jun 2006	A1
20060122653	Bradley et al.	Jun 2006	A1
20060122654	Bradley et al.	Jun 2006	A1
20060135882	Bleich	Jun 2006	A1
20060142753	Francischelli et al.	Jun 2006	A1
20060149278	Abdou	Jul 2006	A1
20060161189	Harp	Jul 2006	A1
20060184175	Schomer et al.	Aug 2006	A1
20060195107	Jones et al.	Aug 2006	A1
20060200153	Harp	Sep 2006	A1
20060200154	Harp	Sep 2006	A1
20060200155	Harp	Sep 2006	A1
20060206115	Schomer et al.	Sep 2006	A1
20060206117	Harp	Sep 2006	A1
20060224078	Hoey et al.	Oct 2006	A1
20060235451	Schomer et al.	Oct 2006	A1
20060235452	Schomer et al.	Oct 2006	A1
20060241648	Bleich et al.	Oct 2006	A1
20060264994	Schomer et al.	Nov 2006	A1
20060276720	McGinnis et al.	Dec 2006	A1
20070010717	Cragg	Jan 2007	A1
20070016097	Farquhar et al.	Jan 2007	A1
20070016185	Tullis et al.	Jan 2007	A1
20070027464	Way et al.	Feb 2007	A1
20070049962	Marino et al.	Mar 2007	A1
20070055215	Tran et al.	Mar 2007	A1
20070055262	Tomita et al.	Mar 2007	A1
20070055263	Way et al.	Mar 2007	A1
20070106219	Grabinsky	May 2007	A1
20070123888	Bleich et al.	May 2007	A1
20070162044	Marino	Jul 2007	A1
20070213733	Bleich et al.	Sep 2007	A1
20070213734	Bleich et al.	Sep 2007	A1
20070213735	Saadat et al.	Sep 2007	A1
20070225703	Schmitz et al.	Sep 2007	A1
20070255162	Abboud et al.	Nov 2007	A1
20070255369	Bonde et al.	Nov 2007	A1
20070260252	Schmitz et al.	Nov 2007	A1
20070270795	Francischelli et al.	Nov 2007	A1
20070276286	Miller	Nov 2007	A1
20070282217	McGinnis et al.	Dec 2007	A1
20080033465	Schmitz et al.	Feb 2008	A1
20080051812	Schmitz et al.	Feb 2008	A1
20080125621	Gellman et al.	May 2008	A1
20080125709	Chang et al.	May 2008	A1
20080146867	Gellman et al.	Jun 2008	A1
20080197024	Simpson et al.	Aug 2008	A1
20080288005	Jackson	Nov 2008	A1

Foreign Referenced Citations (50)

Number	Date	Country
3209403	Sep 1983	DE
4036804	May 1992	DE
359883	Mar 1990	EP
1304080	Apr 2003	EP
1340467	Sep 2003	EP
1207794	May 2004	EP
1315463	May 2005	EP
1611851	Jan 2006	EP
1006885	Sep 2006	EP
2706309	Dec 1994	FR
24065380	Mar 2004	JP
02107459	Mar 1998	RU
WO9734536	Sep 1997	WO
WO9918866	Apr 1999	WO
WO 0108571	Feb 2001	WO
WO0162168	Aug 2001	WO
WO0207901	Jan 2002	WO
WO0234120	May 2002	WO
WO02076311	Oct 2002	WO
WO03026482	Apr 2003	WO
WO03066147	Aug 2003	WO
WO2004002331	Jan 2004	WO
WO2004028351	Apr 2004	WO
WO2004043272	May 2004	WO
WO2004056267	Jul 2004	WO
WO2004078066	Sep 2004	WO
WO2004080316	Sep 2004	WO
WO2004096080	Nov 2004	WO
WO2005057467	Jun 2005	WO
WO2005077282	Aug 2005	WO
WO2005089433	Sep 2005	WO
WO2006009705	Jan 2006	WO
WO2006015302	Feb 2006	WO
WO2006017507	Feb 2006	WO
WO2006039279	Apr 2006	WO
WO2006042206	Apr 2006	WO
WO2006044727	Apr 2006	WO
WO2006047598	May 2006	WO
WO2006058079	Jun 2006	WO
WO2006058195	Jun 2006	WO
WO2006062555	Jun 2006	WO
WO2006086241	Aug 2006	WO
WO2006099285	Sep 2006	WO
WO2006102085	Sep 2006	WO
WO2007008709	Jan 2007	WO
WO2007021588	Feb 2007	WO
WO2007022194	Feb 2007	WO
WO2007059343	Feb 2007	WO
WO2007067632	Jun 2007	WO
WO2008008898	Jan 2008	WO

Related Publications (1)

	Number	Date	Country
	20060258951 A1	Nov 2006	US

Provisional Applications (1)

	Number	Date	Country
	60681864	May 2005	US

Continuation in Parts (2)

	Number	Date	Country
Parent	11375265	Mar 2006	US
Child	11457416		US
Parent	11251205	Oct 2005	US
Child	11375265		US

Spinal access and neural localization

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract